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ABSTRACT OF THE DISSERTATION
Mechanisms of Voltage-Gated Sodium Channel (NaV1.5) Regulation by Intracellular FGFs
by
Paweorn Angsutararux
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2022
Professor Jonathan R. Silva, Chair

Voltage-gated sodium channels (NaV) conduct the inward current responsible for the initiation and
propagation of the electrical signals in myocytes and neurons, known as action potentials (AP).
Precise regulation of cardiac NaV1.5 opening and closing is essential for maintaining a normal heart
beat. A disruption of NaV1.5 function, especially of its inactivation after opening, results in inherited
cardiac arrhythmias such as Long QT Type 3 (LQT3) syndrome. This pathology is caused by an
increase in the late INa that enters myocytes later in the AP and prolongs its duration. Late INa is also
enhanced in acquired diseases such as heart failure (HF). NaV channels are regulated by many
auxiliary subunits, including intracellular Fibroblast Growth Factors (iFGFs). Each iFGF gene
encodes multiple different isoforms, varying in their N-terminal sequences. The interaction between
and regulation of iFGF and NaV channels is isoform specific.
In this dissertation, I investigated the modulation of cardiac NaV1.5 channels by iFGFs that are
highly expressed in human and mouse hearts (FGF12B and FGF13VY). I discovered how the
different iFGFs control NaV1.5 voltage sensing and then modulate NaV channel inactivation
differently. I also demonstrated that FGF12A, which is upregulated in patients with HF, can convey
xii

therapeutic benefits by inhibiting late INa. This result provides new insight into how differential
expression of iFGF isoforms can modulate the adverse pharmacological responses that are observed
in HF patients prescribed with anti-arrhythmic drugs. Lastly, I present a newly developed tool for
studying inactivation dynamics and the interplay between the different components of NaV channel
involved in its inactivation, allowing deeper insight into this essential regulatory mechanism.

xiii

Chapter 1: Introduction

1.1 Cardiac electrical activity
The heart is an electrical organ that pumps blood throughout the body. Its function is regulated through
coordinated electrical signals that drive synchronous contractions of the atria and the ventricles in a timely
manner. The electrical impulse is generated by pacemaker cells in the sinoatrial (SA) node and propagates
through the atrial and ventricular chambers (Nerbonne & Kass, 2005). An excitation of an individual myocyte
results in an action potential (AP), which reflects the sequential activation and inactivation of multiple ion
channels (Zipes et al., 2017). The waveform of AP varies within cardiac regions, as a result of different
underlying ionic currents.
For ventricular myocytes (Fig 1.1), during the upstroke of an AP,
or phase 0, an activation of the voltage-gated sodium channel (NaV)
leads to a large inward current (INa) that depolarizes the membrane
potential. Subsequent activation of the fast transient voltage-gated
outward K+ current (Ito) causes a transient repolarization in phase 1,
seen as the AP notch. The activation of voltage-gated Ca2+ channels
(CaV) by membrane depolarization facilitates Ca2+ influx during
phase 2 plateau. This increase in intracellular Ca2+ is the main
trigger of myocyte contraction. In the last phase of AP (phase 3),
two predominant K+ outward currents (IKs and IKr) repolarize the
Figure 1.1: Ventricular AP and underlying
ionic currents (Adopted from Nerbonne &
Kass, 2005).

membrane potential to its resting value and terminates an AP. A
proper regulation of these ion channels enables the rapid AP
1

propagation to maintain normal cardiac rhythms. Any disruption to this elaborated process can result in lifethreatening arrhythmias.

1.2 Pathogenic late INa
NaV channel fast inactivation happens within a few milliseconds after its activation and limits the amount of
late INa that persists over long depolarization (Ulbricht, 2005). In a normal heart, the late INa presents only
about 0.01 - 1% of the peak INa during an AP plateau phase (Antzelevitch & Nesterenko, 2014). An increase
in the late INa leads to an AP prolongation and a dispersion of repolarization. Both are the substrate for early
afterdepolarization (EAD) and predispose the heart to deadly arrhythmias. Increased intracellular Na+ also
reverses the mode of sodium calcium exchanger (NCX), from Ca2+ efflux to Ca2+ influx, leading to elevated
intracellular Ca2+ or Ca2+ overload. As a result, there are more spontaneous Ca2+ releases from sarcoplasmic
reticulum during diastole (a period of heart relaxation), which lead to more incidents of delayed
afterdepolarization (DAD), another common cause of arrhythmias.
Increased late INa is a well-known pathogenic mechanism underlying many inherited and acquired diseased
conditions. Some examples are discussed below.
1.2.1

Congenital long QT type 3 syndrome

An inherited cardiac arrhythmia that exhibits a prolonged QT interval in ECG recording is known as long QT
(LQT) syndrome. LQT syndrome type 3 (LQT3) is often associated with the gain-of-function mutations in
NaV channels and proteins associated with its regulation. The mutations often impair NaV fast inactivation and
cause elevated late INa, either by delaying the fast inactivation kinetics or promoting the channel reopening
after inactivation. The treatment with specific late INa inhibitors is often successful in preventing arrhythmias.
1.2.2

Heart failure
2

Heart Failure (HF) is a condition where the heart fails to pump blood
efficiently. It is characterized by abnormalities in cardiac rhythm and
contraction. An increase in late INa is an important mechanism
contributing to diseased pathophysiology (Maltsev & Undrovinas,
2008). The likely cause of late INa is an increase in NaV channel late
Figure 1.2: A positive feedback loop
between late INa ([Na]) and
CaMKII activation (Adapted from
Grandi & Herren, 2014).

openings, that can be triggered by multiple conditions such as an
increase in oxidative stress, an elevated intracellular Ca2+ and the
activation of protein kinases CaMKII. A positive feedback loop has

been identified (Fig 1.2). Increased late INa contributes to the high cellular Na+ concentrations, which cause
Ca2+ overload, leading to CaMKII activation. CaMKII then modulates NaV channel resulting in further
increase in late INa. The interruption of this feedback loop, either by reducing late INa or inhibiting CaMKII
activation, shows the improved cardiac function in HF animal models. However, clinical results are less
successful in reversing the end-condition such as death, myocardial infarction, and recurrent ischemia
(Morrow et al., 2007).

1.3 Voltage-gated sodium channel
NaV channels are macromolecular complexes that consist of primary α-subunits and several auxiliary subunits
(de Lera Ruiz & Kraus, 2015). Humans have 9 different NaV α-subunits (NaV1.1-1.9), transcribed from genes
SCN1A-SCN9A. Each NaV subtype shows distinct gating kinetics and functional properties (Goldin, 2001).
The expressions of NaV subtypes also vary in different tissue. In the heart, NaV1.5 is the predominant NaV
channel.
1.3.1

Structure of NaV α-subunit

Mammalian NaV α-subunit is transcribed as a single polypeptide with more than 2000 amino acids. NaV α3

subunit is a pseudo-tetrameric protein that
consists of 4 homologous repeats (I-IV) (Yu

and Catterall, 2003). Each repeat contains 6
membrane segments (S1-S6). The following
section will cover the important domains of a
NaV α-subunit (Fig 1.3).
Voltage sensor domain
Helical segments S1-S4 from each repeat
constitute the voltage sensor domain (VSD),
an important module that enables NaV channel
to sense the change in membrane potential.
On segment S4, every third position has a

Figure 1.3: Cryo-EM structure of rat NaV1.5 (Adapted from
Jiang et al., 2020).
(A) Illustration of overall NaV1.5 structure, showing VSD-I to
VSD-IV and III-IV linker or the inactivation gate. (B) Structure
of the pore module (PM) that forms channel central pore and ion
selectivity filter (SF) bearing DEKA ring. (C) Bottom view of
intracellular activation gate (in square) shows the IFMT motif
binding to allosterically block the pore. (D) The IFMT motif
binding to its receptor.

positively charged residue, usually either
Arginine (R) and Lysine (K), which are also called gating charges. In a sliding helix or helical screw model,
gating charges are held at negative resting membrane potentials by negatively charged residues in S1, S2
and/or S3 segments. Upon membrane depolarization or the change in membrane potential toward positive
values, gating charges are transferred across the membrane from the intracellular to the extracellular side,
across the hydrophobic constriction site (HCS). The outward displacement of the S4 helix is mediated by ionpair interaction with countercharges in other segments of the VSD (Catterall et al., 2017). Though
homologous, each VSD is distinct in its sequences and hence its activation kinetic. All VSDs, however, are
highly coupled and work cooperatively to control NaV channel gating.
Pore Module (PM)
The pore module (PM) is formed by S5, S6 segments and the connecting pore-loop (P-loop). It is arranged
4

next to the peripheral VSD in a domain-swapped architect. The VSD of one repeat is close to the PM of
another. Together, PMs from all 4 repeats make the NaV channel central pore. The inner selectivity filter (SF)
is the narrowest part of the pore formed by P-loop. It contains 4 amino acids, aspartate (D), glutamate (E),
lysine (K), and alanine (A) from repeat I-IV accordingly. This DEKA ring confers the channel selectivity to
Na+ ion by facilitating specific binding of hydrated Na+ ions.
Activation gate
At the intracellular boundary of the channel pore, hydrophobic residues from the intracellular ends of S6
segments form a bundle crossing known as the activation gate. The activations of VSDs are propagated via an
S4-S5 linker to cause conformational changes in S6 segments, leading to an opening of the activation gate in
an iris-like dilation manner.
Inactivation gate
The fast inactivation gate is located in the intracellular linker between repeats III and IV (III-IV linker) (Smith
and Goldin, 1997). The key hydrophobic IFMT motif plugs into the corner of the activation gate and causes
an allosteric pore block (Pan et al., 2018). The IFMT binding site encompasses the S6 segment and the S4S5 linkers of repeats III and IV. Extensive interactions were established along the III-IV helix with the S4-S5
of repeat IV.

C-terminal domain
The NaV C-terminal domain (CTD) is the region following the S6 segment of repeat IV. The CTD consists of
6 α-helices, separated into two main domains: the proximal EF hand-like structure and the distal IQ motif,
resembling a lollipop. The EF-like domain consists of α1- α5 and is the binding site of intracellular fibroblast
growth factor (iFGF), whereas the IQ motif (α6) serves as the interaction site of Calmodulin (CaM). These
two proteins, iFGF and CaM, are important NaV channel auxiliary subunits that we will discuss later.
5

1.3.2

NaV channel gating

Upon membrane depolarization, the VSD activation leads to conformational changes around the intracellular
activation gate. Specifically, in human NaV1.5, the activations of VSD-I, II and III lead to channel gate
opening (Chanda and Bezanilla, 2002) (Varga et al., 2015). The activation of VSD-IV occurs slightly later
to initiate the NaV channel fast inactivation (Capes et al., 2013) (Goldschen-Ohm et al., 2013). The
binding of IFMT motif to its receptor allosterically constricts the intracellular gate and limits Na+ ions
conductance. The interactions along the III-IV linker and the CTD stabilize an inactivation conformation
(Deschenes et al., 2001) (Mantegazza et al., 2001) (Motoike et al., 2004). The unbinding of the IFMT
motif, and the deactivation of the VSD-III and VSD-IV determine the recovery from inactivation (Cha et al.,
1999) (Hsu et al., 2017). This open-state inactivation is crucial for controlling an AP duration. Until NaV
channels recover from an inactivation, they cannot be activated repeatedly.
Apart from an open-state inactivation, at hyperpolarized potentials, channels can inactivate directly from the
closed-state conformation (Aldrich and Stevens, 1983) (Bean, 1981). This closed-state inactivation results
in a smaller number of channels available to open, which can be measured as a steady-state inactivation (SSI)
curve. The voltage-dependence of activation (G-V) curve measures the channel conductance at varying
potentials. The overlap of these two curves presents the window current, or the fraction of channels that
conducts INa.

1.4 NaV auxiliary subunits
The NaV α-subunit is regulated by multiple auxiliary subunits including β-subunit, Calmodulin, and
intracellular fibroblast growth factor (iFGF) (Abriel, 2010).

1.4.1

β-subunits
6

The NaV β subunits can regulate the NaV channel function through multiple mechanisms, including the
modulation of NaV channel expression at the cell membrane, the alteration of NaV channel kinetics, the
mediation of cell adhesion, and the recruitment of cytosolic proteins (Calhoun and Isom, 2014). In humans,
there are 5 isoforms of NaV β-subunits (β1 – β4 and β1b), encoded by SCN1B-SCN4B (Winters and Isom,
2016). All β1-β4 subunits share the same topology with an extracellular N-terminal immunoglobulin (Ig)
domain, a transmembrane segment, and an intracellular C-terminus. The β1b subunit contains only the Nterminal domain. The β2 and β4 subunits interact with NaV α-subunit through covalent disulfide bonds,
whereas β1 and β3 subunits interact with α-subunit non-covalently. In the human heart, the most abundant
isoform is the β1 subunit. Other β isoforms have distinct subcellular localization with differential expression
profiles over embryonic development.
1.4.2

Calmodulin

Calmodulin (CaM) is a Ca2+-sensing protein consisting of two globular domains, N- and C-lobes. Each lobe
contains 2 EF-hand motifs, responsible for Ca2+ binding. The binding of Ca2+ often leads to a change in CaM
conformation, rendering CaM a candidate that regulates Ca2+-dependent change in NaV channel inactivation.
These features, however, are debatable and multiple studies show opposing results. Under elevated Ca2+
concentration, CaM was reported to cause a depolarizing shift in SSI (Gabelli et al, 2016), possibly by
facilitating recovery from inactivation (Johnson et al., 2018). Because of the complexity of CaM regulation
that likely involves various facets of NaV channels, its regulatory mechanisms remain unclear (Armstrong and
Cota, 1991) (Kim et al., 2004).
Multiple models of CaM modulation of NaV channel function were proposed based upon available structures
of CaM under different conditions (i.e. high vs low Ca2+ concentration, the presence vs the absence of iFGF,
etc.) (Pitt & Lee, 2016). A leading model proposed that CaM will interact with the NaV III-IV linker under
elevated Ca2+ concentration (Sarhan et al., 2012) (Gabelli et al., 2014) (Chogot et al., 2011). Usually within
NaV1.5, CaM binds to the IQ motif with high affinity under low Ca2+ conditions (Wang, 2012). An increase in
7

Ca2+ lowers the CaM binding affinities on the CTD, while raising its affinity towards the III-IV linker,
potentially affecting the inactivation gate binding during NaV inactivation.
NaV1.5 mutations on the CTD that reduce CaM binding affinities were found in patients with inherited
arrhythmias such as LQT3 and BrS (Liu et al., 2003) (Musa et al., 2015) (Hennessey et al., 2013). These
mutations were associated with increased late INa, supporting the notion of CaM modulation of NaV channel
inactivation.
1.4.3

Intracellular Fibroblast Growth Factor

Intracellular fibroblast growth factors (iFGFs), also known as fibroblast growth factor homologous factors
(FHFs), are a subfamily of the FGFs (Goldfarb, 2005). iFGFs consist of FGF11-FGF14 and share high
similarities in sequences with other FGFs in the core domain. The lack of secretory signal sequences makes
iFGF non-secreted. Studies have shown that iFGFs play a significant role in the regulation of NaV channel
function. Each iFGF gene can be transcribed into two or more isoforms, differing in the N-terminus. The
regulation of NaV channels is specific to both NaV and iFGF isoforms. The expression of iFGFs also varies
across different tissues. A mutation in FGF12B, which is highly expressed in the human heart, is linked to
cardiac arrhythmia (Hennessey et al., 2013). A NaV1.5 variant that affect the iFGF binding affinity also shows
altered gating kinetics (Musa et al., 2015). So far, the regulatory mechanism of iFGF remains elusive,
especially how different iFGFs cause differential modulatory effects.
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Chapter 2: Mechanisms of intracellular fibroblast
growth factor (iFGF) regulation of human cardiac
sodium channel gating

2.1 Abstract
Voltage-gated sodium (NaV) channels are responsible for the initiation and propagation of action potentials in
neurons and myocytes. The NaV channel α-subunit comprises 4 repeats (I-IV), that contain a voltage sensing
domain (VSD) and a pore module. NaV channel gating is regulated by myriad auxiliary subunits including
intracellular fibroblast growth factors (iFGFs), designated FGF11-14. Their modulation of NaV channel is
iFGF gene specific. We investigated how FGF12B, which is highly expressed in human heart, regulates
cardiac NaV1.5 channel in the Xenopus oocyte heterologous expression system. We compared its regulation to
FGF13VY, which is predominant in mouse heart, to examine iFGF differences in the regulatory mechanism.
Both iFGFs induced depolarizing shifts in steady-state inactivation (SSI) and inhibited a slow component of
inactivation. Relative to FGF12B, FGF13VY caused a larger voltage shift in SSI and a greater reduction in
slower inactivation. Voltage-clamp fluorometry (VCF) revealed the iFGF modulation of VSD-IV activation,
which has been previously linked to inactivation gating. FGF12B facilitated VSD-IV activation by causing a
hyperpolarizing shift in half-maximal voltage (V1/2), whereas FGF13VY accelerated its completion by
increasing slope steepness. By observing NaV1.5 regulation by iFGF chimeras of FGF12B and FGF13VY, we
found a strong correlation between accelerated VSD-IV activation and the reduced slow inactivation
component. Surprisingly, in native mouse myocytes, iFGF effects on shifting SSI matched oocyte data, but
not the modulation of INa decay, suggesting that in native cells there are additional regulatory factors that may
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act through VSD-IV to regulate NaV channel inactivation gating.

2.2 Introduction
Voltage gated sodium (NaV) channels are responsible for the excitation of cardiac myocytes. During the
upstroke of an action potential (AP), the inward current conducted through cardiac NaV1.5 depolarizes
membrane potential and initiates an AP. Precise regulation of NaV1.5 kinetics is essential for proper cardiac
function, and disruption of NaV channel inactivation predisposes the heart to arrhythmias (Noble and Noble,
2006) (Ton et al., 2021). Several mutations in the SCN5A gene that encodes NaV1.5 are linked to congenital
cardiac arrhythmias including long QT type 3 (LQT3) syndrome and Brugada syndrome (Ruan et al., 2009)
(Zhu et al., 2019). The NaV α-subunit is a pseudo-tetrameric protein, composed of 4 repeats. Each repeat
contains 6 α-helical segments (S1-S6) that form voltage sensor domains (VSD) and a central pore module.
The NaV VSD, which contains S1-S4, can be activated upon membrane depolarization. Its activation is
coupled to pore opening and inactivation kinetics (Varga et al., 2015). Evidence showed that the modulation
of VSD activation by NaV auxiliary subunits can affect NaV channel gating (Zhu et al., 2017) (Angsutararux et
al., 2021b).
The NaV α-subunit associates with and is regulated by myriad auxiliary subunits (Abriel and Kass, 2005)
(Meadows and Isom, 2005) (Abriel, 2010), including β-subunits (Calhoun and Isom, 2014), Calmodulin
(CaM) (Gardill et al., 2019) and intracellular fibroblast growth factors (iFGFs) (Yang et al., 2016) (Pitt and
Lee, 2016). iFGFs, also known as fibroblast growth factor homologous factors (FHFs) are a subfamily of the
FGFs, and comprise FGF11-FGF14 (Olsen et al., 2003) (Goldfarb, 2005). iFGF regulation of NaV channel
function was previously demonstrated (Liu et al., 2001) (Liu et al., 2003) (Pablo and Pitt, 2016) (Goldfarb et
al., 2007), and iFGF mutations are associated with inherited cardiac arrhythmias (Hennessey et al., 2013) (Li
et al., 2017), and neurological disorders (Siekierska et al., 2016). Mutations in NaV1.5 that disrupt iFGF
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binding are also linked to cardiac disease (Musa et al., 2015). Each iFGF gene can generate 2 or more
isoforms, distinct in their N-terminal sequences (Munoz-Sanjuan et al., 2000) (Pablo and Pitt, 2016). Past
studies showed that modulation of NaV channel function by iFGF was both gene and isoform specific
(Munoz-Sanjuan et al., 2000) (Liu et al., 2003) (Goetz et al., 2009) (Wang et al., 2011b), and also depended
on NaV channel isoform. In the human heart, the dominant iFGF is FGF12B (Hennessey et al., 2013). To date,
its regulatory mechanism of cardiac NaV1.5 is unknown.
In this study, we investigated the molecular mechanism of FGF12B modulation of NaV1.5 gating, with a
focus on its effect on VSD activation. We compare its regulation to FGF13VY, which is highly expressed in
mouse heart (Wang et al., 2011), to understand how different iFGF regulates NaV channel function differently.

2.3 Results
2.3.1 FGF12B regulates NaV1.5 kinetics via the modulation of VSD-IV activation
The Xenopus oocyte heterologous expression system allows us to study the effect of iFGF on NaV1.5 kinetics
with less complexity of other regulatory proteins including endogenous β-subunits. Ionic current recordings
(Fig 2.1A) showed FGF12B modulation of NaV channel gating. In comparison to NaV1.5 alone, FGF12B coexpression shifted the voltage-dependence of activation (G-V) and steady-state inactivation (SSI) curves
toward depolarizing potentials (Table 2.1) (Fig 2.1B). NaV channel recovery from inactivation was also faster
in the presence of FGF12B, relative to NaV1.5 alone (NaV1.5: ƬR,1 = 2.5 ± 0.2, NaV1.5 + FGF12B: ƬR,1 = 1.9 ±
0.3, p-value = 0.04) (Table 2.2) (Fig 2.1C). Superimposed traces of INa (Fig 2.1D, inset) showed a faster
decay in the presence of FGF12B. To quantify this observation, the normalized peak current decay was fitted
to a bi-exponential function, which provides the better fit than a single exponential equation over all
depolarizing potentials. The two inactivation time constants are in the timescale of a few and several
milliseconds, corresponding to the fast and intermediate modes of inactivation after channel opening (Silva,
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2014) (Silva and Goldstein, 2013a, b). We observed no difference in inactivation time constants (Fig 2.1D),
but in their amplitudes. The calculated fractional amplitude of slower inactivation component was
significantly decreased with FGF12B co-expression (Table 1) (Fig 2.1E). These findings imply FGF12B
impaired a slower component of open-state inactivation.

Figure 2.1: FGF12B modulation of hNaV1.5 kinetics
(A) Exemplary INa traces of hNaV1.5 alone (black) and with FGF12B co-expression (blue) during activation
protocols from a holding potential of -120 mV, stepping up to 40 mV in an increment of 10 mV. (B) Voltage
dependence of activation (G-V) and steady-state inactivation (SSI) curves were shifted towards depolarizing
potentials by the co-expression of FGF12B, relative to hNaV1.5 alone. (C) Recovery from inactivation curves
showed an accelerated recovery from FGF12B co-expression. (D) An overlay of exemplary traces at -20 mV
between hNaV1.5 with and without FGF12B emphasizes the difference observed during peak current decay (inset).
A fitting of peak current decay to a bi-exponential function yields two inactivation time constants (fast and slow)
at various depolarizing potentials. (E) The fractional amplitude of slower inactivation time constant was calculated
and compared between hNaV1.5 alone and with FGF12B co-expression. FGF12B caused a reduction in the
fractional amplitude of slower inactivation.

Next, we employed the voltage-clamp fluorometry (VCF) protocol (Mannuzzu et al., 1996) (Stefani and
Bezanilla, 1998) (Gandhi and Olcese. 2008) (Rudokas et al., 2014) to investigate the mechanism of FGF12B
modulation. A cysteine mutation was introduced into the extracellular linker S3-S4 in each VSD for
15

fluorophore (MTS-TAMRA) tagging. The movement of S4 upon membrane depolarization can be observed
by the change in fluorescence emission reflecting an altered surrounding environment (Varga et a., 2015)
(Zhu et al., 2016). To improve the sensitivity of the technique, the cysteine mutation was created in the
background of WT-LFS (Large Fluorescence Signal), bearing Y1977A-C373Y mutations that ablate a
ubiquitination site and prevent non-specific labeling (Varga et a., 2015). Our previous work showed that the
LFS mutation does not substantially affect NaV channel activation and inactivation kinetics. Specific sites of
cysteine mutations for individual VSDs were based on our past studies (Varga et a., 2015) (Zhu et al., 2017).
Voltage-dependent changes in the fluorescence signal (F-V) curve for each VSD can be used to estimate the
conformational change during VSD activation.

Figure 2.2: FGF12B regulation of individual VSD activation
Voltage-clamp fluorometry (VCF) protocol was used to measure the effect of FGF12B co-expression on the
activation of individual VSD. The voltage-dependence of normalized fluorescence emission (F-V) graphs of VSDI to VSD-IV were shown for hNaV1.5 alone (black) or with FGF12B co-expression (blue). Exemplary fluorescence
traces, corresponding to different depolarizing potentials, were included for each VSD recording. FGF12B shifts
the activation of VSD-IV towards hyperpolarizing potentials.
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The experimental results show that co-expression of FGF12B caused no change in the half-maximal voltages
(V1/2) of VSD-I, VSD-II and VSD-III F-V curves (Fig 2.2). For VSD-III, however, we observed a change at
potentials greater than -50 mV. Multiple lines of evidence suggest that VSD-III can activate in two discrete
steps (Chanda and Bezanilla, 2002) (Hsu et al., 2017) (Zhu et al., 2017). Co-expression of FGF12B did not
affect the initial activation at very hyperpolarized potentials. However, the second translation of VSD-III,
observed as an opposite deflection, during depolarized potentials was affected by FGF12B (Fig 2.2). This
second VSD-III activation was proposed to regulate open-state inactivation (Angsutararux et al., 2021a).
FGF12B induced a significant change VSD-IV F-V, causing a hyperpolarizing shift in V1/2 and a decrease in a
slope factor (k) (Table 2.2) (Fig 2.2). The voltage shift implies that the activation of VSD-IV is facilitated,
whereas the steeper slope reflects an accelerated translation of VSD-IV to complete its activation at less
depolarized potentials. Together these results suggest that FGF12B facilitation of VSD-IV activation
underlies the change in NaV1.5 inactivation.
2.3.2 FGF13VY shows differential modulation of NaV1.5 kinetics and a distinct effect on VSD
regulation
Next, we investigated the FGF13VY effect on NaV1.5. An analysis of recorded ionic current (Fig 2.3A)
comparing NaV1.5 alone and NaV1.5 co-expressed with FGF13VY revealed the shifts in SSI curve toward
depolarizing potentials, with no effect on G-V (Table 2.1) (Fig 2.3B). The change in SSI V1/2 by FGF13VY,
was larger in magnitude than an alteration by FGF12B (NaV1.5 + FGF12B: SSI ΔV1/2 = 8.1 mV, NaV1.5 +
FGF13VY: SSI V1/2 = 14.5 mV). The channel recovery from inactivation was also facilitated by FGF13VY
(NaV1.5: ƬR,1 = 2.5 ± 0.2, NaV1.5 + FGF13VY: ƬR,1 = 1.3 ± 0.1, p-value < 0.001) (Table 2.1) (Fig 2.3C). The
altered current decay by FGF13VY (Fig 2.3D, inset) was due to a reduction in the slower component of
inactivation, as shown by reduced fractional amplitude (Fig 2.3E). Both fast and slower inactivation time
constants remained unaffected (Table 2.1) (Fig 2.3D). A comparison also showed a larger reduction of slower
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inactivation component by FGF13VY than FGF12B, especially at more depolarized potentials.

Figure 2.3: FGF13VY modulation of hNaV1.5 kinetics
(A) Exemplary INa traces of hNaV1.5 alone (black) and with FGF13VY co-expression (orange) during activation
protocols. (B) The G-V and SSI curves revealed the depolarizing shifts in SSI by FGF13VY, relative to hNa V1.5 alone.
(C) Recovery from inactivation was accelerated by FGF13VY co-expression when compared to hNaV1.5 alone. (D)
An overlay of exemplary traces at -20 mV emphasizes the difference observed during peak current decay between
hNaV1.5 alone and with FGF13VY (inset). Two inactivation time constants (fast and slow) from the peak current
decay fit were compared in hNaV1.5 with and without FGF13VY. (E) The fractional amplitude of slower inactivation
time constant was calculated. The plot showed the reduction in the fraction of slower inactivation time constants by
FGF13VY, relative to hNaV1.5 alone.

Investigation of individual VSD activation revealed the impact of FGF13VY on the VSD-I and VSD-IV F-V
curves (Table 2.2) (Fig 2.4). The VSD-I F-V curve was shifted towards positive potentials by FGF13VY coexpression, whereas the VSD-IV F-V curve showed an opposite shift in V1/2 with additional increase in its
slope steepness. The modulation of VSD-I is specific to FGF13VY, and hence is not likely the common
mechanisms shared between iFGFs. Instead, we suspected this might be the result of longer FGF13VY Nterminus that can potentially affect activation gate. We will elaborate on this observation later in the
discussion.
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Figure 2.4: FGF13VY regulation of individual VSD activation
The VCF protocol was used to measure the effect of FGF13VY co-expression on the activation of individual VSD.
The F-V graphs of VSD-I to VSD-IV were shown for hNaV1.5 alone (black) or with FGF13VY co-expression
(orange). Exemplary fluorescence traces were included for each VSD recording.

A comparison between VSD-IV F-V curves of FGF12B and FGF13VY revealed a clear distinction on their
modulation. FGF13VY prominently reduced the slope factor (FGF12B: k = 16.5 ± 1.2, FGF13VY: k = 9.4 ±
1.0, p-value = 0.004), whereas FGF12B shifted V1/2 to more negative potentials (FGF12B: V1/2 = -66.2 ± 2.3
mV, FGF13VY: V1/2 = -60.4 ± 1.3 mV, p-value = 0.04). The unique regulation of VSD-IV activation by
different iFGFs suggests its significance in the differential effects of NaV1.5 kinetics, which we will explore
more in the following section.
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Table 2.1: Fit parameters of NaV1.5 compared to NaV1.5 with FGF12B and FGF13VY co-expressions
Parameter

NaV1.5

NaV1.5 +
FGF12B

NaV1.5 +
FGF13VY

V1/2 (n)
p-value
k
p-value

-37.0 ± 0.6 (5)

-26.2 ± 2.2 (6)
0.012 (*)
6.6 ± 0.4
0.56

-32.3 ± 3.1 (6)
0.30
5.5 ± 0.5
0.56

V1/2 (n)
p-value
k
p-value
ƬR,1 (n)
p-value
ƬR,2

-69.0 ± 0.5 (9)

15.8 ± 1.4

-60.9 ± 0.4 (7)
<0.001 (***)
4.9 ± 0.3
0.081
1.9 ± 0.3 (5)
0.04 (*)
12.5 ± 1.3

-54.5 ± 1.8 (6)
<0.001 (***)
4.7 ± 0.4
0.035 (*)
1.3 ± 0.1 (5)
<0.001 (***)
8.5 ± 1.3

Ƭfast (n)
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow

1.7 ± 0.2 (5)
9.2 ± 0.8
0.13 ± 0.004
1.5 ± 0.2
8.2 ± 0.3
0.18 ± 0.01
1.3 ± 0.1
7.6 ± 0.2
0.19 ± 0.01
1.2 ± 0.1
7.3 ± 0.3
0.18 ± 0.01
1.1 ± 0.1
7.1 ± 0.3
0.16 ± 0.01
1.1 ± 0.1
7.3 ± 0.3
0.14 ± 0.01
1.0 ± 0.1
9.2 ± 1.0
0.1 ± 0.02

1.8 ± 0.2 (6)
10.4 ± 0.9
0.09 ± 0.01
1.5 ± 0.1
8.6 ± 0.5
0.07 ± 0.01
1.2 ± 0.04
7.5 ± 0.2
0.08 ± 0.01
1.0 ± 0.005
6.8 ± 0.1
0.08 ± 0.008
0.9 ± 0.01
6.9 ± 0.1
0.06 ± 0.007
0.8 ± 0.02
7.1 ± 0.2
0.05 ± 0.006
0.8 ± 0.01
7.8 ± 0.4
0.04 ± 0.005

2.3 ± 0.3 (5)
14.9 ± 3.4
0.11 ± 0.02
1.8 ± 0.1
9.9 ± 0.8
0.07 ± 0.01
1.3 ± 0.1
8.4 ± 0.7
0.06 ± 0.01
1.1 ± 0.1
8.2 ± 0.6
0.05 ± 0.008
1.0 ± 0.05
7.9 ± 0.5
0.05 ± 0.008
0.9 ± 0.05
7.5 ± 0.6
0.04 ± 0.007
0.9 ± 0.05
8.0 ± 1.1
0.03 ± 0.005

GV

6.1 ± 0.3

SSI

Recovery

Peak decay
At -30 mV

At -20 mV

At -10 mV

At 0 mV

At 10 mV

At 20 mV

At 30 mV

5.8 ± 0.3
2.5 ± 0.2 (8)
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Table 2.2: Fit parameters of voltage dependence of fluorescence (F-V) curves for all voltage sensor domains
of NaV1.5 alone, and with FGF12B and FGF13VY co-expression
Parameter

NaV1.5

NaV1.5 +
FGF12B

NaV1.5 +
FGF13VY

V1/2 (n)
p-value
k
p-value

-75.2 ± 3.6 (4)

-77.6 ± 4.6 (3)
0.70
21.2 ± 2.7
0.49

-50.1 ± 3.1 (4)
0.002 (**)
13.7 ± 1.2
0.009 (**)

V1/2 (n)
p-value
k
p-value

-51.6 ± 1.8 (5)

-53.1 ± 2.9 (4)
0.68
27.4 ± 2.0
0.36

-53.4 ± 1.7 (5)
0.50
38.7 ± 0.9
0.24

V1/2 (n)
p-value
k
p-value

-149.7 ± 1.6 (10)

-145.6 ± 2.1 (8)
0.4
20.6 ± 0.7
0.84

-153.4 ± 4.3 (6)
0.5
22.0 ± 2.0
0.90

V1/2 (n)
p-value
k
p-value

-52.9 ± 2.0 (8)

-66.2 ± 2.3 (8)
<0.001 (***)
16.5 ± 1.2
0.044 (*)

-60.4 ± 1.3 (8)
0.022 (*)
9.4 ± 1.0
<0.001 (***)

VSD-I FV

19.4 ± 0.9

VSD-II FV

33.0 ± 4.9

VSD-III FV

21.4 ± 0.8

VSD-IV FV

20.5 ± 1.3
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2.3.3 iFGF specific modulation of VSD-IV activation determines the slower component of NaV1.5
inactivation
iFGFs consist of three main domains: the N-terminus, the β-trefoil core and the C-terminus. High similarities
are shared among iFGFs in the core domain (Olsen et al., 2003), which serves as the interaction site with the
NaV C-terminal domain (CTD) (Goetz et al., 2009) (Wang et a., 2012) (Musa et al., 2015) (Hennessey et al.,
2013). If all iFGFs are thought to bind to the same CTD location, it is unknown how iFGFs regulate NaV
channels differently. Previously, a role for the N-terminus on the FGF13 isoform-specific modulation of
NaV1.5 gating was suggested (Lou et al., 2005) (Laezza et al., 2009) (Yang et al., 2016) (Barbosa et al.,
2017). An alignment of FGF12B and FGF13VY sequences showed the largest differences lie in N-terminus
(Fig S2.1A). We hence constructed the iFGF chimeras with swapped N-terminal sequences to test their
specificity on VSD-IV regulation.
We switched the N-terminus of FGF13VY (aa1-72) and FGF12B (aa1-4) in FGF12B/13 (12NTD-13Core13CTD) and FGF13VY/12 (13NTD-12Core-12CTD) chimeras (Fig S2.1B). If the N-terminal domain alone is
sufficient for distinct iFGF effect, we expect the shifts in VSD-IV F-V, G-V and SSI curves by FGF12B/13
and FGF13VY/12 chimeras to resemble FGF12B and FGF13VY accordingly. Instead, these iFGF chimeras
showed distinct modulation of VSD-IV activation, as well as in G-V and SSI (Table 2.3, 2.4) (Fig S2.1C).
Further chimera experiments were conducted in a similar manner. We created 2 additional pairs of chimeras
switching (1) the C-terminus and (2) both N- and C-termini, between FGF12B and FGF13VY. None of the
chimera pairs replicated the regulation of the VSD-IV F-V curve by FGF12B and FGF13VY (Table 2.3, 2.4)
(Fig S2.2). The results suggest that all iFGF domains synergistically contribute to VSD-IV activation.
We used data obtained from these iFGF chimeras to further identify the contribution of unique VSD-IV
regulation to NaV1.5 gating. We measured the V1/2 and k of G-V and SSI, and the fitted inactivation time
constants and the amplitudes from the peak current decay (Table 2.3). The activation of VSD-IV has been
previously shown to facilitate NaV channel fast inactivation (Chahine et al., 1994) (Horn et al., 2000) (Chanda
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and Bezanilla, 2002) (Hsu et al., 2017), and the charge neutralization mutations on IV S4 significantly shift
the SSI V1/2 (Capes et al., 2013). Surprisingly, we found no such correlation between VSD-IV F-V and SSI on
either V1/2 or k (V1/2: R2 = 0.055, k: R2 = 0.39) (Fig 2.5A, B). Similarly, no relationship could be established
between VSD-IV F-V and G-V either (V1/2: R2 = 2.7x105, k: R2 = 0.12) (Fig S2.3A, B). Instead, the slope
factor (k) of VSD-IV F-V curve yielded a good correlation to the slower inactivation time constant and the
fractional amplitude of slower inactivation time constants (Ƭslow: R2 at 0, 10, 20 mV = 0.63, 0.62 and 0.46,
fractional amplitude of Ƭslow: R2 at 0, 10, 20 mV = 0.58, 0.56 and 0.62) (Fig 2.5C, D). The correlation was not
established for the V1/2 of VSD-IV F-V curve (Ƭslow: R2 at 0, 10, 20 mV = 0.29, 0.29 and 0.26, fractional
amplitude of Ƭslow: R2 at 0, 10, 20 mV = 0.004, 0.009 and 0.05) (Fig S2.3C, D).
Together, the results suggest that the slope of VSD-IV F-V is a strong determinant of the slower component
of NaV inactivation. The two parameters from VSD-IV F-V (V1/2 and k) can be used to predict the fractional
amplitude of slower inactivation time constants, with more accuracy than the prediction of SSI V1/2 (R2 values
between actual results and predicted values: Ƭslow = 0.72, SSI V1/2 = 0.58) (Fig 2.5E, F). We showed a steeper
VSD-IV F-V, corresponding to the earlier completion of VSD-IV activation at less depolarized potentials,
contributes to an inhibited slower inactivation component. The lower predictability of SSI V1/2 by VSD-IV FV parameters implies an additional element is needed for iFGF modulation of SSI.
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Figure 2.5: Regression analyses reveal a correlation between VSD-IV activation curve and NaV channel
inactivation kinetics
Linear regression analysis was performed on the results of FGF12B, FGF13VY and iFGF chimeras co-expression.
There is no relationship between VSD-IV F-V curve and SSI, in terms of either half-maximal voltage (V1/2) (A) or
slope factor (k) (B). A relationship was found between the slope factor (k) of VSD-IV F-V curves and the slower
inactivation time constant, shown as the representative at 0 mV depolarization (C). Similar relationship was identified
between the k of VSD-IV F-V curve and the fractional amplitude of slower inactivation time constant (D). Both k and
V1/2 of VSD-IV F-V curves were used to predict the fractional amplitude of slower inactivation time constant better
than SSI V1/2, as shown by the plots between predicted and actual values in (E) and (F) accordingly.
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Table 2.3: Fit parameters of NaV1.5 co-expressed with iFGF chimeras
Parameter

12NTD13Core13CTD

13NTD12Core12CTD

13NTD13Core12CTD

12NTD12Core13CTD

12NTD13Core12CTD

13NTD12Core13CTD

V1/2
k (n)

-48.5 ± 0.6
5.3 ± 0.4 (4)

-45.6 ± 2.7
7.4 ± 0.1 (5)

-43.6 ± 1.7
6.5 ± 0.4 (7)

-36.32 ± 1.2
6.7 ± 0.6 (5)

-45.1 ± 1.3
5.7 ± 0.4 (5)

-26.4 ± 1.6
6.5 ± 0.4 (7)

V1/2
k (n)

-69.9 ± 0.4
6.6 ± 0.3 (4)

-63.4 ± 0.7
5.4 ± 0.1
(13)

-60.7 ± 0.5
5.6 ± 0.1 (9)

-69.0 ± 0.6
5.4 ± 0.1 (7)

-69.1 ± 0.8
6.5 ± 0.1 (5)

-67.7 ± 0.6
5.3 ± 0.1 (6)

V1/2
k (n)

-62.5 ± 2.2
14.5 ± 1.1
(9)

-74.5 ± 2.2
15.6 ± 1.0
(9)

-67.7 ± 1.7
15.2 ± 0.7
(5)

-79.6 ± 2.1
17.9 ± 0.7
(8)

-76.5 ± 2.9
20.9 ± 1.3
(6)

-70.1 ± 0.9
13.7 ± 0.7 (8)

Ƭfast
(n)
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow

1.21 ± 0.06
(6)
6.48 ± 0.26
14.8 ± 1.0
1.08 ± 0.03
6.35 ± 0.17
14.0 ± 1.0
0.99 ± 0.02
6.29 ± 0.03
12.9 ± 1.2
0.90 ± 0.02
5.97 ± 0.06
12.0 ± 1.1
0.86 ± 0.02
6.41 ± 0.33
11.3 ± 1.0

1.31 ± 0.05
(12)
6.86 ± 0.51
8.4 ± 1.0
1.11 ± 0.03
6.95 ± 0.48
7.3 ± 0.6
1.00 ± 0.02
6.98 ± 0.32
6.5 ± 0.5
0.92 ± 0.02
6.93 ± 0.29
5.7 ± 0.4
0.86 ± 0.02
6.99 ± 0.36
5.1 ± 0.4

1.41 ± 0.08
(8)
7.55 ± 0.47
12.0 ± 1.5
1.21 ± 0.05
7.23 ± 0.39
10.8 ± 1.3
1.07 ± 0.05
6.58 ± 0.41
10.0 ± 1.0
0.99 ± 0.04
6.24 ± 0.34
8.4 ± 0.8
0.91 ± 0.04
5.70 ± 0.41
7.8 ± 0.9

1.14 ± 0.04
(8)
5.49 ± 0.14
16.4 ± 0.6
0.99 ± 0.02
5.28 ± 0.14
17.5 ± 0.4
0.91 ± 0.01
5.01 ± 0.18
16.9 ± 0.6
0.85 ± 0.02
4.68 ± 0.23
16.0 ± 0.8
0.79 ± 0.02
4.36 ± 0.28
14.7 ± 0.9

1.12 ± 0.03
(4)
6.37 ± 0.19
16.7 ± 2.1
0.98 ± 0.03
5.92 ± 0.33
17.5 ± 1.7
0.89 ± 0.02
5.51 ± 0.39
16.8 ± 1.7
0.84 ± 0.03
5.13 ± 0.45
15.8 ± 1.7
0.77 ± 0.03
4.75 ± 0.51
14.8 ± 1.7

1.62 ± 0.15
(5)
11.29 ± 1.70
4.8 ± 0.6
1.34 ± 0.09
10. 67 ± 1.34
3.6 ± 0.5
1.09 ± 0.07
9.17 ± 0.72
3.4 ± 0.4
0.94 ± 0.06
8.84 ± 0.75
3.2 ± 0.4
0.87 ± 0.06
9.39 ± 1.32
2.8 ± 0.4

GV

SSI

VSD-IV
FV

Peak
decay
At -20 mV

At -10 mV

At 0 mV

At 10 mV

At 20 mV
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Table 2.4: Fit parameters of VSD-IV F-V curves for iFGF chimeras relative to FGF12B and FGF13VY were
tested for the significance of N-terminus (FGF12B/13 and FGF13VY/12), C-terminus (FGF13VY/12CTD
and FGF12B/13CTD) and both N- and C-terminal domains (FGF12B-13Core and FGF13VY-12Core) via
ANOVA analysis.

ΔV1/2 relative to FGF12B
p-value
Δk relative to FGF12B
p-value

12NTD-13Core13CTD
-3.7 mV
0.48
2.0
0.42

13NTD-13Core12CTD
1.4 mV
0.96
1.3
0.83

12NTD-13Core12CTD
10.3 mV
0.01 (*)
-4.4
0.04 (*)

ΔV1/2 relative to FGF13VY
p-value
Δk relative to FGF13VY
p-value

13NTD-12Core12CTD
14.1 mV
< 0.001 (***)
-6.1
< 0.001 (***)

12NTD-12Core12CTD
19.1 mv
< 0.001 (***)
-8.4
< 0.001 (***)

13NTD-12Core13CTD
-9.6 mV
0.002 (**)
-4.3 mV
0.005 (**)
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2.3.4 iFGF potentially modulates the inactivation gate kinetics, important for the regulation of NaV1.5
SSI
The NaV channel inactivation gate requires an IFMT motif on the III-IV linker that causes an allosteric block
of the channel pore (West et al., 1992) (Pan et al., 2018) (Jiang et al., 2020) (Angsutararux et al., 2021a). A
recent structure of eukaryotic NaVPaS channel hints at possible direct interaction between NaV CTD and IIIIV linker (Shen et al., 2017), which was speculated to regulate NaV inactivation (Gade et al., 2020) (Peters et
al., 2020). iFGF binding was found near this interaction site (Wang et al., 2012) and may affect it.
We conducted a mutagenesis study to (1) remove an inactivation gate (IFM/IQM mutation) (Hartmann et al.,
1994), and (2) sever the interaction between III-IV linker and NaV CTD (E1784K mutation) (Shen et al.,
2017) (Gardill et al., 2018) (Gade et al., 2020). We found that both mutations negate the iFGF-mediated
alterations in SSI and GV, but not the VSD-IV F-V (Table 2.5) (Fig 2.6). The mutations altered VSD-IV F-V
curves, but specific modulatory effects of FGF12B and FGF13VY paralleled the results in WT VSD-IV.
FGF12B still induced pronounced hyperpolarizing shift in V1/2, while FGF13VY distinctly altered the slope
factor. Together, this mutagenesis experiment indicated that the inactivation gate is not responsible for the
regulation of VSD-IV, but instead, is essential for the iFGF-mediated shifts in SSI.
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Figure 2.6: The NaV channel inactivation gate is necessary for iFGF modulation of SSI, but not VSD-IV
activation
(A) The IFM/IQM mutation was introduced to impair the NaV channel fast inactivation gate (IFMT motif) and to
investigate its significance on iFGF modulation. The co-expressions of FGF12B and FGF13VY no longer cause the
shifts in SSI in IQM channel (left). Both FGF12B and FGF13VY induce the similar shifts in the G-V curves (left).
However, the VSD-IV F-V curves (right) show similar alterations by iFGFs as in WT VSD-IV. (B) The E1784K
mutation interferes with the interaction between NaV CTD and III-IV linker. This mutation negates the shifts in SSI
and G-V by FGF12B and FGF13VY (left) but does not alter the VSD-IV activation curves (right).
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2.3.5 iFGF effects in mouse ventricular myocytes
As reported in other studies (Wang et al., 2011a) (Park et al., 2016), we found that FGF13VY is the
predominant isoform expressed in mouse ventricles. We generated the mouse model of global FGF13
knockout (FGF13KO) and tested the NaV channel gating in isolated ventricular myocytes. In comparison to
WT and Floxed mice, the deletion of FGF13 did not affect the peak INa density (Fig 2.7A, Fig S2.4A), nor the
voltage-dependence of NaV channel activation (Table 2.6) (Fig 2.7B). Floxed mice were used as negative
control, to ensure the Cre-lox system does not affect INa (Fig 2.7B). In FGF13KO myocytes, we observed a
shift in SSI toward hyperpolarizing potentials (Table 2.6) (Fig 2.7B), consistent with the results from
Xenopus oocytes. The recovery from inactivation was not altered by the FGF13 knockout (WT: ƬR,1 = 8.1 ±
1.4, FGF13KO: ƬR,1 = 6.3 ± 0.9, p-value = 0.26) (Table 2.6) (Fig 2.7C).
The alteration in the peak current decay can be noticed in FGF13KO. The decay fitted to a double exponential
function showed unaffected inactivation time constants but reduced fractional amplitude of slower
inactivation component in FGF13KO myocytes (Table 2.6) (Fig 2.7D, E). This change is in the opposite
direction from the results obtained in Xenopus oocytes. In mouse myocytes, the INa decays faster when FGF13
was absent, due to the reduction in slower component of inactivation (Fig 2.7E). Similar knockout of
FGF12B in mice (FGF12B KO) did not alter any kinetics of the INa in ventricular cardiomyocytes (Table 2.6)
(Supplementary Fig 2.4B). This result is expected, given that FGF12B is not expressed in the mouse
ventricle.
We then introduced FGF12B in the FGF13KO mice and found that the SSI was shifted back towards
depolarizing potentials, but not as positive as in WT mice (Table 2.6) (Fig 2.8A, B). We also observed the
shift in G-V curve by FGF12B plasmid in FGF13KO mice towards depolarizing potentials (Fig 2.8B). A
reduction in peak current density was not significant (Fig S2.4A). The presence of FGF12B enhanced the
recovery from inactivation (FGF13KO: ƬR,1 = 6.3 ± 0.9, FGF13KO + FGF12BT: ƬR,1 = 4.0 ± 0.6, p-value =
0.04) (Table 2.6) (Fig 2.8C) but did not alter the inactivation kinetics. The fast and slower inactivation time
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constants, as well as the fractional amplitude of slower inactivation were not affected by FGF12B expression
in FGF13KO myocytes (Table 2.6) (Fig 2.8D, E).

Figure 2.7: The effect of FGF13 in FGF13-knockout, relative to wild-type mice
(A) Exemplary INa traces from mouse ventricular myocytes of wild-type (WT) (black), and FGF13-knockout
(FGF13KO) (orange) mice. (B) The voltage dependence of activation curve (G-V) was not affected by FGF13
knockout. However, the knockout of FGF13 caused a hyperpolarizing shift in steady-state inactivation (SSI) curve
relative to WT and Flox (grey) mice. (C) The recovery from inactivation curves are not different between WT and
FGF13KO mice. (D) The peak current decay traces were fitted to a double exponential function and the fast (open
symbol) and slower (filled symbol) inactivation time constants were plotted. There was no differences between WT
and FGF13KO mice in terms of inactivation time constant at hyperpolarizing potentials, but at depolarizing potentials,
the knockout of FGF13 slowed down the slower inactivation. (E) The fractional amplitude of slower inactivation time
constant was reduced upon FGF13 knockout over all membrane potentials.

Altogether, we observe similar effects of FGF12B and FGF13 in mice models on G-V and SSI curves, as in
Xenopus oocytes. Deviations in inactivation kinetics between two expression systems imply complex gating
that is influenced by other factors present in mouse myocytes such as β-subunits and post-translational
modifications that may directly affect VSD-IV activation.
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Figure 2.8: The effect of FGF12B in FGF13-knockout mice
(A) Exemplary INa traces from mouse ventricular myocytes of FGF13-knockout (FGF13KO) (orange), and FGF12B
expressed in FGF13KO (FGF13KO + FGF12B) (blue) mice. (B) The GV and SSI curves were shifted towards
depolarizing potentials by FGF12B expressed in FGF13KO mice (blue vs orange). The shift in SSI by FGF12B
expression is not as depolarized as in WT (black) mice. (C) The recovery from inactivation was enhanced by FGF12B
expression, relative to FGF13KO mice. (D) The fast (open symbol) and slower (filled symbol) inactivation time
constants were not altered by FGF12B expression in FGF13KO mice. (E) The fractional amplitude of slower
inactivation time constant was not affected by FGF12B expression, in comparison to FGF13KO mice.
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Table 2.5: Fit parameters of IQM and E1784Q NaV1.5 alone and with FGF12B and FGF13VY co-expression
Parameter

IQM NaV1.5

IQM NaV1.5 +
FGF12B

IQM NaV1.5 +
FGF13VY

V1/2 (n)
p-value
k
p-value

-20.7 ± 1.0 (5)

-30. 6 ± 0.7 (3)
< 0.001 (***)
7.7 ± 0.9
0.5

-31.8 ± 0.4 (4)
< 0.001 (***)
5.2 ± 0.6
0.003 (**)

V1/2 (n)
p-value
k
p-value

-41.6 ± 0.7 (5)

-43.0 ± 0.9 (3)
0.3
3.4 ± 0.1
0.9

-43.6 ± 0.4 (4)
0.1
4.0 ± 0.4
0.5

V1/2 (n)
p-value
k
p-value

-59.7 ± 0.9 (3)

-70.5 ± 1.3 (3)
0.002 (**)
7.0 ± 0.5
0.97

-54.4 ± 1.5 (3)
0.05 (*)
4.2 ± 1.5
0.1

E1784K NaV1.5

E1784K NaV1.5 +
FGF12B

E1784 K NaV1.5
+ FGF13VY

V1/2 (n)
p-value
k
p-value

-20.7 ± 0.8 (5)

-20.2 ± 0.9 (5)
0.95
9.0 ± 0.3
0.9

-25.0 ± 1.7
0.04 (*)
7.2 ± 0.3
< 0.001 (***)

V1/2 (n)
p-value
k
p-value

-101.9 ± 0.9 (5)

-113.3 ± 4.1 (5)
0.04 (*)
19.3 ± 0.5
0.01 (**)

-91.8 ± 3.7 (4)
0.09
16.5 ± 1.6
0.3

V1/2 (n)
p-value
k
p-value

-60.9 ± 2.9 (4)

-64.8 ± 2.3 (3)
0.5
17.1 ± 1.8
0.7

-56.1 ± 1.0 (3)
0.3
12.9 ± 1.1
0.1

GV

8.5 ± 0.3

SSI

3.6 ± 0.2

VSD-IV FV

7.3 ± 0.9

GV

9.1 ± 0.1

SSI

14.9 ± 0.3

VSD-IV FV

19.5 ± 2.5
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Table 2.6: Fit parameters of INa recordings from mouse myocytes
Parameter
G-V

V1/2 (n)

SSI

p-value
k
p-value
V1/2 (n)

Recovery
Peak decay
At -20 mV

At -25 mV

At -20 mV

At -15 mV

At -10 mV

At -5 mV

At 0 mV

At 5 mV

At 10 mV

p-value
k
p-value
ƬR,1 (n)
ƬR,2
Ƭfast (n)
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow

WT

Flox

FGF13 KO

FGF12B KO

-46.3 ± 0.6
(24)

-44.1 ± 1.0
(15)
0.11
2.9 ± 0.2
0.46
-72.8 ± 1.3
(15)
0.97
7.1 ± 0.1
0.84

-44.6 ± 0.8
(19)
0.24
3.7 ± 0.2
0.79
-70.1 ± 1.0
(19)
0.06
7.2 ± 0.1
> 0.99

8.1 ± 1.4 (7)
87.8 ± 18.4

-44.4 ± 0.6
(26)
0.12
4.0 ± 0.1
0.12
-82.5 ± 0.8
(26)
< 0.001 (***)
6.7 ± 0.2
0.02 (*)
6.3 ± 0.9 (9)
58.9 ± 8.4

1.4 ± 0.1 (13)
6.1 ± 0.3
0.12 ± 0.02
1.2 ± 0.05
5.3 ± 0.3
0.11 ± 0.02
1.1 ± 0.05
4.8 ± 0.2
0.11 ± 0.02
1.0 ± 0.04
4.4 ± 0.2
0.095 ± 0.02
0.9 ± 0.04
4.1 ± 0.2
0.081 ± 0.01
0.9 ± 0.04
4.2 ± 0.3
0.061 ± 0.01
0.8 ± 0.04
4.1 ± 0.4
0.052 ± 0.02
0.8 ± 0.05
5.1 ± 0.7
0.035 ± 0.01
0.7 ± 0.05
6.6 ± 1.4
0.034 ± 0.01

1.0 ± 0.1 (12)
5.5 ± 0.5
0.041 ± 0.004
0.9 ± 0.1
4.7 ± 0.4
0.043 ± 0.003
0.8 ± 0.1
4.4 ± 0.3
0.039 ± 0.003
0.75 ± 0.07
4.3 ± 0.4
0.031 ± 0.003
0.71 ± 0.07
4.5 ± 0.5
0.022 ± 0.003
0.67 ± 0.07
4.3 ± 0.8
0.018 ± 0.002
0.64 ± 0.07
5.0 ± 1.3
0.013 ± 0.002
0.61 ± 0.07
5.8 ± 1.4
0.010 ± 0.002
0.58 ± 0.07
8.3 ± 2.3
0.012 ± 0.002

3.6 ± 0.1
-73.4 ± 1.0
(24)
7.2 ± 0.1
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FGF13KO +
FGF12B
-37.48 ± 0.9
(19)
< 0.001 (***)
4.3 ± 0.1
0.006 (**)
-77.2 ± 0.5
(17)
0.02 (*)
6.9 ± 0.1
< 0.001 (***)
4.0 ± 0.6 (9)
28.2 ± 2.8
1.1 ± 0.1 (4)
5.7 ± 0.5
0.047 ± 0.01
1.0 ± 0.08
4.4 ± 0.2
0.055 ± 0.01
0.9 ± 0.06
4.1 ± 0.2
0.056 ± 0.01
0.8 ± 0.07
4.1 ± 0.4
0.044 ± 0.002
0.8 ± 0.05
4.0 ± 0.3
0.038 ± 0.002
0.7 ± 0.05
4.5 ± 0.5
0.024 ± 0.003
0.7 ± 0.05
5.8 ± 1.3
0.014 ± 0.002
0.6 ± 0.04
7.7 ± 0.9
0.011 ± 0.005
0.6 ± 0.03
14.2 ± 1.6
0.013 ± 0.007

2.4 Discussion
NaV channels in cardiac cells are formed by macromolecular complexes, modulated by myriad auxiliary
subunits. Study of the underlying mechanism of particular subunits within a native myocyte environment
could be challenging. In this work, we employed the heterologous expression system of Xenopus oocytes to
delineate the mechanistic detail of iFGF modulation of cardiac NaV1.5 function and compared to native cell
regulation.
2.4.1 Differential modulations of NaV1.5 by FGF12B and FGF13VY
We studied the effects of FGF12B and FGF13VY on human NaV1.5. We chose two 2 highly expressed iFGFs
in human and mouse hearts as the representatives of different iFGFs. In Xenopus oocytes, both iFGFs induced
the same depolarizing shift in SSI, but a larger magnitude of alteration in V1/2 by FGF13VY. Both FGF12B
and FGF13VY caused the faster decay of INa, which can be characterized as the reduction in the slower
component of inactivation. A comparison also showed differences in the magnitude of this reduction, a larger
reduction by FGF13VY, more prominently at depolarized potentials.
Although we observed a depolarizing shift in G-V by FGF12B, further investigation showed it was likely due
to the tightly coupled activation and inactivation kinetics (Keynes, 1992). In mutant NaV1.5 that we remove
the inactivation gate (IQM mutation), FGF12B no longer caused the shift in SSI, nor the G-V. The faster
inactivation, induced by iFGF, potentially leading to the reduction in the apparent channel conductance and
hence the shift in G-V. The larger amount of channel availability in the presence of FGF13VY could negate a
shift in the G-V curve by iFGF.
2.4.2 Distinct iFGF regulation of VSD-IV activation
The VCF results revealed the effects of FGF12B and FGF13VY on the regulation of VSD-IV activation.
Their distinct modulation on VSD-IV F-V curve was observed, and can be characterized by differences in
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Boltzmann fit parameters, V1/2 and k. Both iFGFs induced the hyperpolarizing shift in V1/2 and the steeper
slope or reduced k, but with differing degree of alteration. The prominent FGF12B effect is in V1/2, shifting it
to more hyperpolarized potentials, whereas FGF13VY markedly decreased k to a smaller value. The
hyperpolarizing shift in V1/2 indicates the facilitated activation of VSD-IV at less depolarized potentials, while
the steeper slope signifies the accelerated completion of VSD-IV activation due to more charges being
transferred.
Previous VCF studies demonstrated that the activation of VSD-IV correlates to the onset of fast inactivation
(Chanda and Bezanilla, 2002) (Capes et al., 2013). Site-3 toxins, that bind to the extracellular loop near IV S4
and inhibit the outward translation of VSD-IV, prevent the NaV channel transition into fast inactivation
(Hanck and Sheets, 2007) (Campos et al., 2004). This implies the full activation of VSD-IV is necessary for
the entry into the fast inactivated state (Campos and Beirão, 2006) (Campos et al., 2008) (Jiang et al., 2021a)
(Jiang et al., 2021b). Modulation by both FGF12B and FGF13VY is consistent with the decrease in the slower
component of channels inactivation from open state. In other words, iFGF promotes fast inactivation, by
facilitating the VSD-IV activation and accelerating its completion.
This modulation of VSD-IV may be the direct effect of iFGF binding to the NaV C-terminal domain (CTD) as
hypothesized previously from the chimeric structures of NaVPaS-hNaV1.7 in complex with the α-scorpion
toxin (Clairfeuille et al., 2019). The resting conformation of VSD-IV was shown to interact with the NaV
CTD, which in turn sequesters the III-IV linker (Clairfeuille et al., 2019). Although the nature of this
interaction is called into question by the non-functionality of NaVPaS channel and the absence of resolved
CTD in other hNaV channels, the mutations that likely disrupt this interaction were tested in NaV1.5 to support
the claim. The binding of iFGF could affect the conformation of the CTD so that it breaks contact with VSDIV and as a result VSD-IV can activate at hyperpolarizing potentials.
The sole modulation of VSD-I activation by FGF13VY suggests the possible role of long N-terminus in
altering the coupling between VSDs of different repeats. Multiple electrophysiological studies supported the
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tightly coupled interactions between VSDs (Vandenberg and Bezanilla, 1991) (Keynes and Elinder, 1998)
(Chanda et al., 2004) (Campos et al., 2008), especially between repeats I and IV where the domain-swapped
architecture places the VSD-I close to S5-S6 of repeat IV. However, the binding of local anesthetic (LA)
drugs to the channel pore can modify the coupling between VSDs (Muroi and Chanda, 2009). Possibly, the
long FGF13VY N-terminus might interact with the channel pore and remodel the coupling interactions
between voltage sensors (White et al., 2019) (Yan et al., 2014). FGF12B, which bears much shorter Nterminus hence lacks its effect on VSD-I activation.
2.4.3 iFGF chimera experiments reveal the significance of VSD-IV activation on NaV1.5 inactivation
We used chimera experiments to identify the key iFGF domain responsible for its unique VSD-IV regulation.
Surprisingly, results showed that not only N-terminus, but all three domains combined (N-terminus, core, and
C-terminus) contribute to unique regulatory effect of each iFGF. According to the structures of NaV1.5 CTD
in complex with FGF13 and calmodulin (Goetz et al., 2009) (Wang et a., 2012) (Musa et al., 2015)
(Hennessey et al., 2013), the iFGF binding sites reside within the core domain. Interestingly, the FGF12
structures show that its C-terminal residues can interact with the core region, and possibly the N-terminus
(Goetz et al., 2009). A disruption of NaV channel and iFGF interaction interfaces at different sites leads to
differential effects on INa (Singh et al., 2021). These evidence supports the possibility that unique sequence of
iFGF leads to differential binding conformation on the NaV CTD and consequently its distinct modulation of
VSD-IV activation.
We then used results from iFGF chimera experiments to analyze the significance of VSD-IV activation on
NaV channel gatings, by performing linear regression analysis. We discovered a good correlation and a high
predictability by VSD-IV parameters on INa decay kinetics, in particular the slower inactivation time constants
and the fraction of channels undergoing this mode of inactivation. Further mutagenesis study revealed the
iFGF-mediated shifts in SSI requires the inactivation gate, and the interaction between NaV CTD and III-IV
linker. iFGF potentially affects the interaction of NaV CTD and III-IV linker, that is essential for the release of
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an inactivation gate.
Based upon the two-switch model proposed by Clairfeuille et al., during resting state, the NaV CTD can
interact with (1) VSD-IV S4 and (2) III-IV linker (Clairfeuille et al., 2019). The activation of VSD-IV severs
the first interaction and subsequently releases III-IV linker from the CTD. The binding of iFGF might
modulate these two interactions in two ways: (1) iFGF reduces the CTD interaction with VSD-IV and
promotes its activation (2) iFGF enhances the CTD interaction with III-IV linker and reduces the probability
of closed-state inactivation, resulting in an increased steady-state channel availability (Angsutararux et al.,
2021a). iFGF also facilitates recovery from inactivation, the process depending on both the movement of
IFMT motif and VSD-III and VSD-IV deactivation (Hsu et al., 2017).
2.4.4 Physiological significance
The Xenopus oocytes heterologous expression system provides insight into mechanisms of iFGF regulation of
NaV channel gating. We observed in FGF13KO mice the consistent effects of iFGF modulation of NaV1.5 GV and SSI. Previous studies reported a similar FGF13 effect on the modulation of SSI in mice myocytes
(Wang et al., 2011a) (Park et al., 2016) (Wang et al., 2017) (Park et al., 2020). Yet, there were some
dissimilarities between studies. Past experiments reported the reduced INa amplitude and a slower recovery
from inactivation upon FGF13 knockout or knockdown (Wang et al., 2011a) (Park et al., 2016) (Wang et al.,
2017) (Park et al., 2020). However, we observed no change in either peak current density of the rate of
recovery from inactivation, in comparison to WT and Floxed mice. The disagreement might arise from the
different technique used for gene knockout or variations in recording protocols. The effects of FGF12B were
also translated from Xenopus oocytes to mouse myocytes. Even the magnitude difference in the shifts of V1/2
between FGF12B and FGF13VY, was reflected in the mouse model.
The kinetics of NaV channel inactivation, however, were different between 2 expression systems. As
demonstrated in previous study (Park et al., 2016), the knockout of FGF13 caused an apparently faster current
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decay. An analysis showed the reduced fraction of slower inactivation component in FGF13KO mice, which
is the opposite effect of FGF13VY reported in Xenopus oocytes. This discrepancy might be due to the
presence of other factors in native cardiomyocyte that can also affect the VSD-IV activation and hence
inactivation kinetics, such as β-subunit (Zhu et al., 2017) (Zhu et al., 2021), Calmodulin (CaM) and
intracellular Ca2+ (Gade et al., 2020) (Abrams et al., 2020). Post-translational modifications like
phosphorylation can also affect the binding of iFGF on the CTD (Burel et al., 2017) (Iqbal and LemmensGruber, 2019) (Lorenzini et al., 2021). The synergistic effects of multiple regulatory proteins can potentially
lead to these deviations perceived between different study systems.

2.5 Conclusion
In this study, we demonstrated the significant regulation of VSD-IV activation by iFGF. The facilitated
activation and accelerated completion of VSD-IV movement by iFGF reduce the slower component of
inactivation, after channel opening. We also showed the differential magnitude of SSI shifts by FGF12B and
FGF13VY are the result of distinct iFGF regulation of VSD-IV activation kinetics, and potentially a
modulation of CTD interaction with III-IV linker. FGF13VY induced a larger depolarizing shift in SSI
because of its faster completion of VSD-IV activation, contributing to the less fraction of channel entering
slower mode of inactivation. As a result, with FGF13VY, channels can recover faster and thus the larger
number of channels are available to open. The ability to modulate VSD-IV activation, however, is not unique
to iFGF. Other regulatory proteins such as β-subunits, toxins, and antiarrhythmic drugs could all modulate
VSD-IV and cause distinct effects in NaV channel inactivation kinetics. Our work suggests a new mechanistic
model of NaV channel regulation that relies on VSD-IV as a signaling hub to determine inactivation gating.
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2.6 Materials and Methods
2.6.1 Molecular biology
Point mutations were made in SCN5A, FGF12B and FGF13VY genes with the QuikChange II site-directed
mutagenesis kit (Agilent) with primers from Sigma-Aldrich containing the mutation. The DNA of iFGF
chimeras was synthesized by GeneArt Gene Synthesis (Thermo Fisher Scientific). All mutations and chimeras
were confirmed with DNA sequencing. The complementary RNA (cRNA) was synthesized with the
mMessage mMACHINE T7 Transcription kit (Life Technologies) after linearizing DNA with appropriate
restriction enzyme and purifying with the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel). The final
cRNA was reconstituted with ddH2O to a concentration of ~1 µg/µl.
2.6.2 Cut-Open oocyte and voltage-clamp fluorometry (VCF)
Oocytes were harvested from Xenopus laevis by laparotomy according to an animal protocol approved by the
Washington University Animal Studies Committee, and digested with collagenase (Sigma-Aldrich, St. Louis,
MO). Oocytes were injected with cRNAs and incubated in ND93 solution (93 NaCl mM, 5 KCl mM, 1.8
CaCl2 mM, 1 MgCl2 mM, 5 HEPES mM, 2.5 Na pyruvate mM, and 1% penicillin–streptomycin, pH 7.4) at
18°C for 3-6 days prior to recording. A total of 50-56 ng cRNA was injected per oocyte. For iFGF coexpression experiments, iFGF was co-injected with hNaV1.5 at a 4:1 molar ratio.
Cut-open recordings were performed at 19°C with a temperature controller (HCC-100A; Dagan Corporation),
using a cut-open amplifier (CA-1B; Dagan Corporation) coupled to an A/D converter (Digidata 1440;
Molecular Devices). Data were collected through Clampex software (Molecular Devices) and analyzed with
Clampfit (Molecular Devices). The internal recording solution was composed of 105 mM NMG-Mes, 10 mM
Na-Mes, 20 mM HEPES, and 2 mM EGTA, at a pH level of 7.4 and the external recording solution contained
25 mM NMG-Mes, 90 mM Na-Mes, 20 mM HEPES, and 2 mM Ca-Mes2, at a pH level of 7.4.
For VCF, the oocytes were labeled for 30 minutes on ice with 10 µmol/L of methanethiosulfonate39

carboxytetramethylrhodamine (MTS-TAMRA; Santa Cruz Biotechnology) in a depolarizing solution
composed of 110 mM KCl, 1.5 mM MgCl2, 0.8 mM CaCl2, 0.2 mM EDTA and 10 mM HEPES at a pH of
7.1. Simultaneous recordings of ionic current and fluorescence emissions were collected on a custom rig
(Rudokas et al., 2014) (Varga et al., 2015) (Zhu et al., 2017). Fluorescence emission was measured by a
photodiode (PIN-040A; United Detector Technology) and a patch clamp amplifier (Axopatch-200A;
Molecular Devices), after teal LED light illumination by the SPECTRA X (Lumencor, OR).
2.6.3 Electrophysiology data analysis
Recordings were analyzed with Clampfit (Molecular Devices), and Excel (Microsoft). Steady-state activation
protocols were tested from -120 to 60 mV for 100 ms with -120 mV pre- and post-pulses holding for 100 ms.
The calculated conductance was normalized to the maximum conductance at 20 mV. For steady-state
inactivation curve, cells were preconditioned at voltages ranging from -150 to 20 mV for 200 ms, the channel
availability was then tested at -20 mV. The normalized conductance-voltage (G-V), and steady-state
inactivation (SSI) curves were fitted to a Boltzmann equation (Eq.1).
G(V) = 1/(1+exp[-(V-V1/2)/k])

(Eq.1)

where V1/2 is the half-activation voltage and k is the slope factor
Fast inactivation kinetics were calculated by fitting the peak current decay to a double exponential function
(Eq.2).
I(t) = offset - a1exp(t/тfast) - a2exp(t/тslow)

(Eq.2)

where a1 and a2 are amplitudes for fast and slow components of inactivation and тfast and тslow are time
constants of inactivation.
Recovery from inactivation was determined by a double pulse protocol with varying recovery duration
between two pulses. The first depolarizing pulse was applied at -20 mV for 200 ms to induce the fast
inactivation and the second 20 ms pulse at -20 mV pulse was used to test the channel availability after
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recovery period. The recovery duration was measured from 1-1000 ms. The normalized recovery curve was
fit to a double exponential equation (Eq.3).
I(t) = offset - a1exp(t/тR,1) - a2exp(t/тR,2)

(Eq.3)

where a1, a2 are the current amplitudes at non-zero recovery and тR,1, тR,2 are the recovery time constants.
The fluorescence signals were low-pass filtered at 1kHz and corrected for photo-bleaching following baseline
subtraction. A fluorescence trace obtained at -120 mV, which is the holding potential, was fitted as a model
for the calculation of baseline traces with no change in fluorescence at other potentials. The voltagedependence of normalized steady-state fluorescence emission (F-V) curve was fitted to a Boltzmann equation
(Eq.4).
F(V) = 1/(1+exp[(-V-V1/2)/k])

(Eq.4)

Statistical analyses were performed using Student’s t-tests, linear regression and multiple linear regression
with Prism9 (Graph Pad, CA).
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2.8 Supplementary Figures

Figure S2.1: Investigation of iFGF N-terminus on the isoform-specific regulation of NaV1.5
(A) An alignment of FGF12B and FGF13VY sequences showed their significant difference in N-terminus. High
sequence similarities were found in the iFGF core domain, whereas the C-terminus portrays the difference between the
type of iFGF. (B) An illustration of iFGF chimeras with swapped N-terminus (FGF12B/13 and FGF13VY/12) and
original iFGFs. (C-E) The measurements of steady-state inactivation (SSI) (C), voltage-dependence of activation (GV) (D), and the VSD-IV voltage-dependence of steady-state fluorescence (F-V) curves of NaV1.5 co-expressed with
FGF12B/13 (blue triangle, solid line) and FGF13VY/12 (orange diamond, solid line) were compared to Na V1.5 alone
(black, dashed line), with FGF12B (blue, dashed line) and with FGF13VY (orange, dashed line) co-expression.
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Figure S2.2: The iFGF chimeras experiment reveals the significance of unique iFGF sequence on the
modulation of VSD-IV activation
The VSD-IV F-V curves of iFGF chimeras (black, circle) were compared to those of FGF12B (blue, dashed line) and
FGF13VY (orange, dashed line), in order to test the significance of different parts of iFGF. Two iFGFs were swapped
for N-terminus (left), C-terminus (middle), or both N- and C-termini (right) and tested for their modulation of VSD-IV
activation. Results show none of the swapped pairs can sufficiently replicate the results of FGF12B and FGF13VY
modulation, indicating the significance of the unique sequence of iFGF stemming from all the iFGF parts.
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Figure S2.3: Linear regression analyses of iFGFs and iFGF chimeras reveal no relationship between VSD-IV
modulation and G-V curves
There is no correlation found between the VSD-IV F-V and the G-V curves, for either V1/2 (A) or k (B). The V1/2 of
VSD-IV F-V also does not show correlation to the inactivation kinetics, parameterized as inactivation slow time
constant (C) and its fractional amplitude (D).
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Figure S2.4: The knockout of FGF12B causes no change in INa, relative to WT mouse ventricular myocytes
(A) The peak current density voltage curves showed no alteration in the peak I Na of FGF13 knockout (orange), and
FGF12B expressed in FGF13KO (blue), relative to WT (black) and Flox (grey) mice.
(B) The peak current density voltage curve (left) and voltage dependence of activation and steady-state inactivation
curves (right) showed no alteration in FGF12B knockout (blue), relative to WT(black) mice.
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Chapter 3: NaV channel accessory subunit, FGF12A, is
the late INa inhibitor of cardiac NaV1.5

3.1 Abstract
Cardiac voltage-gated sodium (NaV1.5) channels are responsible for the cardiac tissue excitability. Its
activation leads to a large inward Na+ current (INa), that depolarizes membrane potential during the upstroke
of an action potential (AP). Fast inactivation occurs a few milliseconds later and facilitates AP termination.
When NaV channel inactivation is incomplete, residual INa that persists long after fast inactivation (late INa) is
enhanced, predisposing the heart to arrhythmias. This phenomenon is observed in several acquired diseased
conditions including heart failure (HF). Increased late INa leads to enhanced expression and activation of
CaMKII, which can further mediate an increase in late INa, establishing the positive feedback loop. The
specific late INa inhibitor shows promising therapeutic potential. However, drug therapy targeting late INa was
not yet successful in reversing conditions of HF patients. In this study, we demonstrated the crucial role of
FGF12A, which we found upregulated in failing hearts, in the pathophysiology of cardiac diseases. FGF12A
is an intracellular fibroblast growth factor (iFGF) and is an important regulator of NaV channel function. It
caused a depolarizing shift in NaV channel steady-state inactivation (SSI) and a reduction in slower
component of NaV fast inactivation. We illustrated its ability to inhibit late INa in the inactivation deficient
NaV channels. This switch of iFGF isoforms presents natural protective mechanism. FGF12A expression can
modulate the pharmacology and sensitivity of specific late INa inhibitor like Ranolazine. This work presents
the new paradigm of late INa with adaptive mechanism in pathophysiology of HF.
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3.2 Introduction
Cardiac voltage-gated sodium (NaV1.5) channels mediates the excitability of myocytes. The activation of NaV
channels gives rise to inward Na+ current (INa) during the upstroke of an action potential (AP) (Yu and
Catterall, 2003). Shortly after, NaV channels inactivate and limit INa, allowing other outward currents to
hyperpolarize membrane potential and terminate an AP. In normal heart, late INa persisted long-after the fast
inactivation is small, relative to peak INa (Mangold et al., 2017). When the fast inactivation is compromised,
elevated level of late INa could be detrimental and predisposes the heart to arrhythmias (Antzelevitch and
Nesterenko, 2015). Enhanced late INa is the common mechanism observed in congenital heart diseases such
as long QT type 3 (LQT3) syndrome (Dumaine et al., 1996) and in acquired conditions such as heart failure
(HF) (Horvath and Bers, 2014).
When late INa is increased, the AP duration is prolonged, making the heart susceptible to arrhythmia (Horvath
et al., 2013). Additionally, increased intracellular Na+ can affect intracellular Ca2+, through the sodium
calcium exchanger (NCX), and lead to diastolic dysfunction (Sossalla et al., 2011). Increase in Ca2+
concentration also enhances the expression and activation of CaMKII, which promotes the positive feedback
loop through CaMKII-mediated increase of late INa (Wagner et al., 2006) (Maltsev et al., 2008) (Aiba et al.,
2010) (Ma et al., 2012). An increase in late INa were found among cardiomyocytes from end-stage HF patients
and in HF animal models (Maltsev et al., 2007) (Valdivia et al., 2005) (Maltsev et al., 1998). The treatment of
HF with specific late INa inhibitor such as Ranolazine showed promising therapeutic benefits (Scirica et al.,
2007) (Antzelevitch et al., 2011). However, in the clinical trials, Ranolazine failed to reverse the myocardial
infarction or severe recurrent ischemia in patients (Morrow et al., 2007). What causes the unsuccessful
outcome of this treatment is not well understood.
The primary NaV α-subunit comprises 4 repeats (I-IV). Each repeat contains 6 membrane segments (S1-S6),
with S1-S4 constituting voltage sensing domain (VSD) and S5-S6 forming the Na+-selective pore. NaV
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channel function is often regulated by auxiliary subunits such as intracellular fibroblast growth factors
(iFGFs) or fibroblast growth factor homologous factors (FHFs) (Goldfarb et al., 2007) (Goetz et al., 2009)
(Pitt and Lee, 2016) (Yang et al., 2016) (Barbosa et al., 2017) (Effraim et al., 2019). iFGFs are a subfamily of
FGFs, sharing high similarities in their sequences (Goldfarb, 2005) (Ornitz and Itoh, 2015). FGF11-FGF14
lack the secretion signal sequences (Munoz-Sanjuan et al., 2000) (Olsen et al., 2003), and are retained
intracellularly (Olsen et al., 2003). Each iFGF exists in various isoforms, originating from an alternative
splicing in its N-terminus (Munoz-Sanjuan et al., 2000). The expression pattern of iFGFs varies across
different tissues (Goldfarb, 2005) (Munoz-Sanjuan et al., 2000) (Wang et al., 2000) (Wang et al., 2011a), and
within subcellular compartments (Rush et al., 2006) (Xiao et al., 2013). The interaction between NaV channel
and iFGFs is also isoform specific (Wang et al., 2011b) (Lou et al., 2005) (Liu et al., 2003). The iFGFmediated modulation of NaV channel kinetics is distinct between different isoforms (Yang et al., 2016)
(Barbosa et al., 2017) (Effraim et al., 2019) (Rush et al., 2006) (Wittmack et al., 2004) (Laezza et al., 2009).
We recently illustrated the unique regulatory mechanism of iFGF through NaV1.5 VSD modulation
(Angsutararux et al., 2022, in preparation).
In neurons, iFGFs A-isoform regulates the repetitive firing frequency by inducing the long-term inactivation
of neuronal NaV channels (such as NaV1.2, NaV1.6) (Dover et al., 2010) (Yan et al., 2014) (Venkatesan et al.,
2014). An inactivation particle was identified on the N-terminus of iFGF A-isoform (Dover et al., 2010) (Yan
et al., 2014) (Venkatesan et al., 2014) (Navarro et al., 2020). This inactivation particle is conserved across Aisoform of all iFGFs. In human hearts, FGF12B is the predominant iFGF (Hennessey et al., 2014). FGF12
gene can encode two isoforms, FGF12A and FGF12B. In this study, we observed an increase in the
expression of FGF12A isoform in HF patients. The role and mechanism of FGF12A on cardiac NaV1.5 is not
yet established. Here, we demonstrated the significance of FGF12A on the regulation of NaV1.5 function,
particularly on its modulation of late INa in pathogenic conditions. We further investigated its implications on
the HF treatment.
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3.3 Results
3.3.1 FGF12A expression is upregulated in the human failing heart
In normal human hearts, FGF12B is most highly expressed among iFGF isoforms in both atria and ventricles
(Fig 3.1A). There showed some expressions of FGF12A, and less of FGF13s. In the failing ventricles, an
increase in the expression of FGF12A and a reduction in FGF12B expression was detected (Fig 3.1B). There
was no difference in the expression of FGF13 isoforms in the failing, compared to normal hearts.

Figure 3.1: The expression of FGF12A is increased in heart failing ventricle
In the normal human heart, the predominant iFGF in both atria and ventricles is FGF12B (left), while FGF12A is also
expressed at lower amount. The expression of FGF12A was found to increase in failing ventricles compared to the
normal heart, whereas the FGF12B expression is reduced (right).

3.3.2 FGF12A alters NaV1.5 inactivation kinetics
FGF12A was injected with human NaV1.5 at a 4:1 molar ratio to ensure complete interaction for all NaV
channels studied. INa was measured for NaV1.5 alone or with FGF12A co-expression (Fig 3.2A). The steadystate inactivation (SSI) curve was shifted by FGF12A toward depolarizing potentials, while the voltage
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dependence of activation (G-V) curve was not affected (Table 3.1) (Fig 3.2B). The recovery from
inactivation also showed no alteration by FGF12A (Table 3.1) (Fig 3.2C). A comparison of INa traces
between NaV1.5 alone and with FGF12A co-expression demonstrated the distinct inactivation kinetics, over
the first 10 ms of activation (Fig 3.2D, insets). The normalized peak current decay can be best fitted to a biexponential function across membrane potentials. Two inactivation time constants are in the range of a 1s and
10s ms. They are defined as fast and intermediate inactivation, which is faster than the conventional slow
inactivation occurring in the range of 100s ms to seconds. We found that FGF12A did not significantly alter
the inactivation time constants (Table 3.1) (Fig 3.2D). However, the fractional amplitude of intermediate
inactivation relative to the fast inactivation were significantly decreased by FGF12A co-expression across all
depolarizing potentials (Table 3.1) (Fig 3.2E). We showed here that FGF12A modulates the NaV channel
inactivation completion at steady state, as well as the fraction of channels undergoing fast vs intermediate
inactivation during its fast kinetics.

Figure 3.2: The electrophysiological study of FGF12A modulation of human cardiac Na V1.5
(A) The INa recordings of hNaV1.5 (black) and hNaV1.5 co-expressed with FGF12A (red) in Xenopus oocytes were shown.
(B) The co-expression of FGF12A shifts the steady-state inactivation (SSI) curve towards positive potentials, without
affecting the voltage dependence of activation (G-V).
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Table 3.1: Fit parameters of NaV1.5 compared to NaV1.5 with FGF12A co-expressions reported as mean ±
S.E.M
Parameter

NaV1.5

NaV1.5 +
FGF12A

V1/2 (n)
p-value
k
p-value

-37.0 ± 0.6 (5)

-40.4 ± 0.9 (5)
0.6
4.5 ± 0.7
0.1

V1/2 (n)
p-value
k
p-value
Ƭf (n)
p-value
Ƭs (n)

-69.0 ± 0.5 (9)

15.8 ± 1.4

-62.6 ± 0.5 (6)
<0.001 (***)
6.0 ± 0.3
0.97
2.2 ± 0.1 (6)
0.4
22.4 ± 3.9

Ƭfast (n)
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow
Ƭfast
Ƭslow
Aslow

1.7 ± 0.2 (5)
9.2 ± 0.8
0.13 ± 0.004
1.4 ± 0.2
8.1 ± 0.4
0.17 ± 0.006
1.2 ± 0.1
7.5 ± 0.3
0.19 ± 0.01
1.1 ± 0.1
7.1 ± 0.3
0.18 ± 0.01
1.1 ± 0.1
6.9 ± 0.3
0.15 ± 0.01
1.0 ± 0.08
7.1 ± 0.3
0.13 ± 0.01
0.98 ± 0.06
9.3 ± 1.1
0.09 ± 0.01

1.8 ± 0.1 (5)
10.1 ± 0.6
0.098 ± 0.01
1.5 ± 0.1
8.7 ± 0.3
0.07 ± 0.01 (***)
1.3 ± 0.06
8.8 ± 0.6
0.08 ± 0.01 (***)
1.1 ± 0.06
8.5 ± 0.5 (*)
0.07 ± 0.006 (***)
1.0 ± 0.05
8.1 ± 0.4 (*)
0.06 ± 0.006 (***)
0.95 ± 0.05
8.0 ± 0.3
0.05 ± 0.005 (***)
0.8 9 ± 0.04
8.6 ± 0.6
0.04 ± 0.006 (**)

GV

6.1 ± 0.3

SSI

Recovery

Peak decay
At -30 mV

At -20 mV

At -10 mV

At 0 mV

At 10 mV

At 20 mV

At 30 mV

5.8 ± 0.3
2.5 ± 0.2 (8)

Figure 3.2 (Continue): (C) The time course of recovery from inactivation is similar between NaV1.5 alone
and with FGF12A (ƬR NaV1.5: 1.8 ± 0.1 ms, ƬR NaV1.5+FGF12A: 1.9 ± 0.1 ms, p-value = 0.4). (D) An
overlay of normalized INa at -20 mV shows the accelerated decay for the first 10 ms (inset). The normalized peak
current decay was best fitted to a double exponential function across multiple potentials. The fast and slower
inactivation time constants are similar between NaV1.5 and NaV1.5 with FGF12A. (E) The fractional amplitude of
slower inactivation time constants was significantly reduced by FGF12A across depolarizing potentials.
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3.3.3 The modulation of FGF12A on VSD-IV activation
We investigated the mechanisms of FGF12A modulation through the voltage-clamp fluorometry (VCF)
technique (Rudokas et al., 2014). The fluorescence dye (MTS-TAMRA) was tagged to an individual voltage
sensor domain (VSD), allowing its conformational change to be detected. Simultaneous recordings of
electrical current INa and the fluorescence signal gives insights into the kinetics of VSD activation at (Cha &
Bezanilla, 1997) (Zhu et al., 2016).

Figure 3.3: FGF12A alter the activation of VSD-IV
The voltage clamp fluorometry (VCF) technique was applied to study the FGF12A effect on individual VSD. The
exemplary traces of fluorescence signal at various depolarizing potentials were shown. The change in steady-state
emission was normalized and plotted against testing potentials. The voltage dependence of fluorescence emission (FV) curves showed no difference between NaV1.5 (black) and NaV1.5 with FGF12A co-expression (red) in the
activation of VSD-I to VSD-III. However, FGF12A accelerates the completion of VSD-IV activation, shifting the
V1/2 of the curve toward hyperpolarizing potential as well as decreasing the slope factor k (Na V1.5: V1/2 = -54.7 ± 1.4
mV, k = 18.2 ± 1.0, NaV1.5+FGF12A: V1/2 = -70.0 ± 1.2 mV, k = 10.6 ± 0.9; p-value V1/2 < 0.001, p-value k <
0.001).
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The voltage dependence of steady-state fluorescence signal (F-V) curves were examined for each repeat with
and without FGF12A co-expression (Fig 3.3). There was no alteration in the F-V curves of VSD-I, II and III
(Table 3.2) by FGF12A. However, pronounced shift in half maximal voltage (V1/2) towards hyperpolarizing
potentials was observed for VSD-IV F-V when co-expressed with FGF12A (NaV1.5 V1/2: -54.7 ± 1.4 mV,
NaV1.5 + FGF12A V1/2: -66.2 ± 2.3 mV) (Table 3.2) (Fig 3.3). The slope factor (k) of VSD-IV F-V was also
altered (NaV1.5 k: 28.2 ± 1.0, NaV1.5 + FGF12A k: 10.6 ± 0.9) (Table 3.2), indicating an earlier and faster
movement of this VSD.
Table 3.2: Fit parameters of voltage dependence of fluorescence (F-V) curves for all voltage sensor domains
of NaV1.5 alone, and with FGF12A co-expression
Parameter

NaV1.5

NaV1.5 +
FGF12A

V1/2 (n)
p-value
k
p-value

-75.7 ± 3.5 (4)

-78.0 ± 2.6 (4)
0.62
20.7 ± 2.0
0.42

V1/2 (n)
p-value
k
p-value

-51.6 ± 1.8 (5)

V1/2 (n)
p-value
k
p-value

-150.7 ± 1.5 (9)

V1/2 (n)
p-value
k
p-value

-54.7 ± 1.4 (6)

VSD-I FV

18.8 ± 0.9

VSD-II FV

33.0 ± 4.9

-48.3 ± 1.7 (3)
0.27
22.7 ± 1.2
0.11

VSD-III FV

21.4 ± 0.8

-157.4 ± 3.1 (6)
0.051
22.7 ± 1.0
0.33

VSD-IV FV

28.2 ± 1.0

-66.2 ± 2.3 (8)
<0.001 (***)
10.6 ± 0.9
<0.001 (***)

3.3.4 FGF12A acts as inactivation particle when NaV channel inactivation gate is impaired
NaV channel fast inactivation involves the inactivation gate (IFMT motif) on III-IV linker binding to its
receptor, and allosterically blocking the Na+ conduction (Pan et al., 2018) (Jiang et al., 2020) (Angsutararux et
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al., 2021a). To test whether this inactivation gate, is required for FGF12A-mediated modulation of NaV
inactivation, we made an IFM/IQM mutation.

Figure 3.4: FGF12A promotes open-state inactivation in an inactivation-impaired NaV1.5
(A) The mutation of IFMT motif to IQM in NaV1.5 impairs the fast inactivation, leading to the sustained late I Na
(black). An expression of FGF12A induces secondary inactivation in IQM Na V1.5, resulting in reduced level of late
INa. (B) The SSI curves of IQM NaV1.5 exhibits an incomplete inactivation at depolarizing potentials, while the
FGF12A co-expression increases the steady-state inactivation. There is no difference in the V1/2 of SSI curves (IQM
NaV1.5: -41.6 ± 0.7 mV, IQM NaV1.5+FGF12A: -41.7 ± 0.9 mV, p-value = 0.99). (C) The time course of recovery
from inactivation for IQM NaV1.5 with FGF12A showed the delayed period with no recovery during the first 10 ms.
This hints to the possible different deactivation kinetics of FGF12A from the IFMT motif. (D) The peak current
decay of IQM NaV1.5 was best fitted to a single exponential equation. The inactivation time constants are similar
between the NaV channels with and without FGF12A. (E) The late INa was measured as the average current during the
last 10 ms of the 100-ms depolarizing pulse, normalized to the peak current. There is significant reduction in % late
INa by FGF12A across membrane potentials (filled black circle vs filled red square) (*, **, *** indicate p-values less
than 0.05, 0.01, and 0.001 accordingly).

The resulting inactivation impaired IQM NaV1.5 showed noticeable level of late INa, which is significantly
reduced upon FGF12A co-expression (Fig 3.4A). The quantification of late INa over the last 10 ms of 100-ms
depolarization pulse demonstrated FGF12A ability to reduce late INa across all depolarizing potentials (Table
3.3) (Fig 3.4E). With FGF12A, the inactivation proceeded long after the first few ms toward the entire
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duration. The SSI curve also showed a significant reduction in the NaV channel conductance at depolarizing
potentials in the presence of FGF12A, which translates to a higher amount of NaV channels with complete
inactivation (Fig 3.4B). Interestingly, there is no longer the shift in SSI V1/2 by FGF12A in IQM NaV1.5 (Fig
3.4B). Removal of the inactivation gate nullified the FGF12A modulation of NaV SSI, implying its
significance in FGF12A regulatory mechanisms.
The recovery from inactivation curve revealed the unique mechanism of FGF12A inactivation particle (Fig
3.4C), featuring the lagging phase where no channel recovers from inactivation. The inactivation kinetic of
IQM NaV1.5, as quantified by the peak current decay, was now best fitted to a single exponential function.
We observed similar inactivation time constants for IQM NaV1.5 with and without FGF12A, even though the
final level of steady-state inactivation was different (Fig 3.4D). The inactivation time constants of FGF12A,
however, were distinct from WT NaV1.5 fast and intermediate inactivation. This altogether implies the unique
inactivation mechanism of FGF12A inactivation particle.
Past studies identified the N-terminus of iFGF A-isoform (amino acid 2-21) as the inactivation particle for
long-term inactivation of neuronal NaV channels (Dover et al., 2010) (Venkatesan et al., 2014), we tested the
specificity of this region in FGF12A and cardiac NaV1.5. The deletion of the inactivation particle sequence
made FGF12A ineffective in reducing late INa of IQM NaV1.5 (Fig S3.1). The A-isoform of FGF13 which
contains the same inactivation particle sequence (Fig S3.2A) can also reduce late INa (Fig S3.2B, C) and
increase steady-state inactivation completion (Fig S3.2D). The recovery from inactivation with FGF13A
displayed the lagging phase as observed with FGF12A (Fig S3.2E). Together, these showed the N-terminus
of iFGF A-isoform bears the inactivation particle that can rescue cardiac NaV1.5 inactivation when the
inactivation gate was impaired.
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Table 3.3: Averaged % late INa for IFM/IQM NaV1.5, alone or with FGF12A measured before and after
Ranolazine treatment

Parameter

Before
Ranolazine

After Ranolazine

% late INa (n)
p-value
% block
% late INa (n)
p-value
% block
% late INa (n)
p-value
% block
% late INa (n)
p-value
% block

52.7 ± 2.7 (10)

39.0 ± 2.4 (7)
0.003 (**)
25.2 ± 4.0
27.0 ± 1.8 (7)
< 0.001 (***)
27.0 ± 3.9
21.3 ± 1.7 (7)
0.001 (**)
29.5 ± 3.8
16.4 ± 0.9 (7)
< 0.001 (***)
36.1 ± 3.6

% late INa (n)
p-value
% block
% late INa (n)
p-value
% block
% late INa (n)
p-value
% block
% late INa (n)
p-value
% block

13.7 ± 1.0 (10)

IQM NaV1.5
-40 mV

-30 mV

-20 mV

-10 mV

38.4 ± 1.6 (10)

32.9 ± 2.2 (10)

30.1 ± 2.3 (10)

IQM NaV1.5+
FGF12A
-40 mV

-30 mV

-20 mV

-10 mV

12.1 ± 1.2 (10)

10.2 ± 1.2 (10)

9.0 ± 1.1 (10)
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11.7 ± 1.1 (7)
0.2
23.2 ± 8.1
9.2 ± 0.5 (7)
0.06
34.5 ± 5.9
7.2 ± 0.5 (7)
0.06
39.4 ± 6.7
5.8 ± 0.7 (7)
0.04 (*)
49.7 ± 7.1

3.3.5 FGF12A reduces late INa in LQT3-linked NaV1.5 variants on III-IV linker
An inherited cardiac disease long-QT type 3 (LQT3) syndrome is caused by mutations in NaV1.5 that
enhances late INa, leading to the prolonged QT interval. A treatment with late INa blocker serves as an effective
therapy (Nagatomo et al., 2000). Here, we tested whether FGF12A can reduce late INa in LQT3-linked NaV1.5
variants. These variants are usually found along locations, involved in the regulation of NaV channel
inactivation, such as III-IV linker (Kapplinger et al., 2015). We studied three variants, F1473S, ΔK1500, and
ΔKPQ (Zhu et al., 2019) (Fig 3.5A). The current recording at -20 mV showed noticeable level of late INa for
these 3 variants (Fig 3.5D). The SSI curves also showed non-zero conductance at high depolarizing potential,
an implication of incomplete inactivation (Fig 3.5E). The expression of FGF12A with these LQT3-linked
variants led to the significant reduction in late INa, with great efficiency over 50% (Table 3.4) (Fig 3.5B). The
steady-state availability also decreased with FGF12A co-expression, in addition to its depolarizing shift in
V1/2 (Table 3.5) (Fig 3.5C, D). Indeed, two variants, ΔK1500 and ΔKPQ, showed almost complete
inactivation in the presence of FGF12A. We demonstrated here the potential of FGF12A as a late INa inhibitor
for LQT3 treatment.
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Figure 3.5: FGF12A acts as a late INa inhibitor in LQT3-linked NaV1.5 variants
(A) An illustrated figure shows mutations in III-IV linker, that are found in patients with long QT type 3 (LQT3)
syndrome. (B) All LQT3-linked NaV variants exhibited the late INa that was significantly reduced by FGF12A. (C)
The comparison of SSI V1/2 between LQT3-linked NaV1.5 variants alone (grey) and with FGF12A (red). (D)
Exemplary traces of LQT3-linked INa, compared between in the absence and presence of FGF12A (black vs red).
Insets showed the level of late INa during the last 10 ms. (E) The incomplete steady-state inactivation was decreased
by the co-expression of FGF12A (inset), reducing the channel conductance at depolarizing potentials almost to zero.
The SSI curves were also shifted by FGF12A towards positive potentials.
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Table 3.4: % late INa of LQT3-linked NaV1.5 variants, alone or with FGF12A co-expression
Variants
F1473S
ΔK1500
ΔKPQ
D1790G
Y1795C
E1901Q
S1904L
Q1909R
IQ/AA
WT

NaV1.5
% late INa (n)
p-value
% late INa (n)
p-value
% late INa (n)
p-value
% late INa (n)
p-value
% late INa (n)
p-value
% late INa (n)
p-value
% late INa (n)
p-value
% late INa (n)
p-value
% late INa (n)
p-value
% late INa (n)
p-value

18.7 ± 1.6 (5)
2.4 ± 0.6 (4)
2.5 ± 0.2 (5)
0.9 ± 0.1 (5)
4.5 ± 1.3 (4)
1.0 ± 0.6 (10)
2.6 ± 0.6 (5)
0.8 ± 0.1 (4)
0.7 ± 0.1 (4)
1.2 ± 0.4 (5)
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NaV1.5 +
FGF12A
10.9 ± 1.1 (8)
0.002 (**)
0.7 ± 0.1 (4)
0.025 (*)
0.3 ± 0.1 (5)
< 0.001 (***)
0.4 ± 0.1 (7)
0.01 (*)
0.7 ± 0.5 (4)
0.03 (*)
0.4 ± 0.1 (6)
< 0.001 (***)
1.0 ± 0.2 (5)
0.03 (*)
0.7 ± 0.2 (4)
0.73
0.7 ± 0.2 (4)
0.89
0.7 ± 0.2 (5)
0.27

Table 3.5: Fit parameters of SSI curves for all LQT3-linked NaV1.5 variants alone, and with FGF12A coexpression
Variants
F1473S
ΔK1500
ΔKPQ

D1790G

Y1795C

E1901Q

S1904L

Q1909R

IQ/AA

NaV1.5
SSI V1/2 (n)
p-value
SSI k
SSI V1/2 (n)
p-value
SSI k
SSI V1/2 (n)
p-value
SSI k
SSI V1/2 (n)
p-value
SSI k
SSI V1/2 (n)
p-value
SSI k
SSI V1/2 (n)
p-value
SSI k
SSI V1/2 (n)
p-value
SSI k
SSI V1/2 (n)
p-value
SSI k
SSI V1/2 (n)
p-value
SSI k

-66.0 ± 1.2 (4)
7.2 ± 0.5
-80.2 ± 1.9 (4)
11.3 ± 0.6
-69.0 ± 1.6 (4)
7.3 ± 0.2
-83.9 ± 1.4 (4)
5.6 ± 0.1
-77.9 ± 4.9 (4)
5.6 ± 0.2
-66.6 ± 3.0 (8)
5.3 ± 0.1
-69.1 ± 0.3 (5)
5.2 ± 0.3
-75.0 ± 1.0 (4)
6.7 ± 0.2
-78.5 ± 2.2 (7)
6.5 ± 0.2
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NaV1.5 +
FGF12A
-58.7 ± 1.7 (4)
< 0.001 (***)
8.7 ± 0.2
-93.2 ± 0.5 (3)
0.006 (**)
9.9 ± 0.6
-73.3 ± 1.8 (4)
0.002 (**)
6.2 ± 0.2
-71.4 ± 1.2 (6)
< 0.001 (***)
4.6 ± 0.1
-57.3 ± 1.3 (4)
< 0.001 (***)
5.5 ± 0.5
-49.8 ± 1.0 (4)
< 0.001 (***)
4.0 ± 0.2
-54.5 ± 2.0 (5)
< 0.001 (***)
5.3 ± 0.3
-62.3 ± 0.9 (5)
< 0.001 (***)
5.6 ± 0.4
-59.8 ± 1.8 (5)
< 0.001 (***)
7.3 ± 0.2

3.3.6 FGF12A induces a large shift in SSI V1/2 when NaV1.5 variants disrupt CaM binding on the CTD
Next, we tested the LQT3-linked variants registered to the C-terminal domain (CTD) of NaV1.5, which
contains the binding sites of iFGF and Calmodulin (CaM) (Wang et al., 2012). We picked 5 LQT3-linked
variants, D1790G (Liu et al., 2003) (Abriel et al., 2000), Y1795C (Vecchietti et al., 2007) (Rivolta et al.,
2001), E1901Q (Kapplinger et al., 2009), S1904L (Bankston et al., 2007), and Q1909R (Tester et al., 2005)
(Fig 3.6A). Three variants, E1901Q, S1904L, and Q1909R are located within the CaM-binding motif (IQ
motif) (Yan et al., 2017), whereas D1790G and Y1795C are in the globular or the EF-hand domain. These
two amino acids D1790 and Y1795 are shown in the interaction interface between two NaV1.5 CTDs (Gabelli
et al., 2014). The EF-hand domain was also proposed to interact with III-IV linker during inactivation (Gardill
et al., 2018). Except D1790G (Liu et al., 2003), the rest of these LQT3-linked variants were reported to
display enhanced late INa as arrhythmogenic mechanism.
In our Xenopus oocytes heterologous system, however, only Y1795C and S1904L showed substantially larger
late INa, than WT NaV1.5 (Table 3.4) (Fig 3.6B). Even the IQ/AA NaV1.5, that abolishes the binding site of
CaM, showed non-significant late INa. Still, FGF12A was effective in reducing late INa for Y1795C and
S1904L (Table 3.4) (Fig 3.6D), showing approximately the same % reduction efficiency as in LQT3-linked
variants in III-IV linker (Fig 3.6B). Interestingly, the expression of FGF12A with Y1795C NaV1.5 delayed
its fast inactivation, as observed by distinctively slowed peak current decay (Fig 3.6D). The SSI curves of all
LQT3-linked variants in the CTD were shifted towards depolarizing potentials by FGF12A (Table 3.5), with
the inactivation mostly complete at steady state (Fig 3.6C, E). The shifts in SSI V1/2 by FGF12A,
nevertheless, were larger among NaV1.5 variants on the CTD, relative to WT and LQT3-linked variants on
III-IV linker (Fig S3). The magnitude of the change was largest in IQ/AA NaV1.5. The difference here
suggests the significance of CaM binding towards FGF12A regulation of NaV1.5.
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Figure 3.6: Effects of FGF12A on LQT3-linked NaV1.5 variants located at the C-terminal domain
(A) An illustrated figure shows mutations in the C-terminal domain (CTD) that are found in patients with long QT type
3 (LQT3) syndrome (B) FGF12A reduced late INa in 2 NaV1.5 variants, Y1795C and S1904L. The rest of the LQT3linked NaV1.5 variants did not show significant increase in late INa, relative to WT NaV1.5. (C) The comparison of SSI
V1/2 between LQT3-linked NaV1.5 variants alone (grey) and with FGF12A (red). (D) The exemplary INa traces of LQT3linked NaV1.5 variants (black) alone and with FGF12A co-expression (red). Insets show the late INa during the last 10
ms of the depolarizing pulse. (E) SSI curves demonstrated the FGF12A-modulated shifts towards depolarizing
potentials for all LQT3-linked variants on NaV1.5 CTD, as well as the more complete inactivation (insets).
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3.3.7 FGF12A modulates late INa blocker, Ranolazine
We demonstrated the ability of FGF12A to reduce late INa in the inactivation-impaired NaV channels. We then
wanted to test how FGF12A affects the efficacy of the specific late INa blocker like Ranolazine. Studies
showed that accessory proteins such as B-subunit can modulate the sensitivity of the NaV channels to
antiarrhythmic drug (Zhu et al., 2021). We found that in IFM/IQM NaV1.5, Ranolazine caused the significant
reduction in % late INa (Table 3.3) (Fig 3.7A, B). However, when FGF12A was co-expressed, % late INa
before and after Ranolazine treatment were no longer significantly different (Table 3.3) (Fig 3.7A, B).
FGF12A was more potent in blocking late INa than Ranolazine in in IQM NaV1.5, yielding smaller % late INa.
Still, the efficacy of Ranolazine in inhibiting late INa was not affected by the presence of FGF12A (Fig 3.7C).
Rather, FGF12A greatly reduced late INa in such a way that further reduction by Ranolazine appeared
insignificant. The modulatory effect of FGF12A, instead, altered Ranolazine block of INa peak current (Fig
3.7A, D). Significantly larger reduction in peak INa by Ranolazine was observed with FGF12A co-expression,
as comparison to IQM NaV1.5 (Fig 3.7D). In the presence of FGF12A, Ranolazine was more effective in
inhibiting peak, rather than late INa in IQM NaV1.5, especially at less depolarized potentials. This modification
of peak INa inhibition by FGF12A, however, was not observed in WT NaV1.5 (Fig S3.4A). Ranolazine yielded
similar tonic block (TB) and use-dependent block (UDB) in WT NaV1.5, regardless of the expression of
FGF12A (Fig S3.4B).
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Figure 3.7: FGF12A expression modulates the pharmacology of specific late INa inhibitor Ranolazine
(A) Exemplary traces of IQM (top) and IQM with FGF12A (bottom) before and after Ranolazine. The drug induces the
reduction in both peak and late INa. (B) The % late INa, relative to peak INa, of IQM NaV1.5 was significantly reduced by
Ranolazine and FGF12A at all potentials. However, Ranolazine failed to cause significant reduction in % late I Na when
IQM NaV1.5 was co-expressed with FGF12A. (C) The % inhibition of late INa by Ranolazine was similar in IQM
NaV1.5 with and without FGF12A. (D) FGF12A increased Ranolazine inhibition of peak INa.

3.4 Discussion
When the heart fails to pump blood efficiently, multiple adaptations are triggered as compensatory
mechanisms (Kemp and Conte, 2012) (Jackson et al., 2000). Some mechanisms such as cardiac remodeling
may lead to eventual deterioration of cardiac function, while some are believed to have protective effects
70

(Mann, and Bristow, 2005). These alterations can also happen at the cellular level in cardiac myocytes (Dash
et al., 2001).
In cardiomyocytes isolated from left ventricle of heart failure (HF) patients, we observed an increase in the
expression of FGF12A and a reduction of FGF12B. This alteration hints to the possible novel adaptative
mechanisms upon HF. In this study, we demonstrated the therapeutic potential of FGF12A in
pathophysiology of heart diseases, and how its expression might affect the treatment by specific late INa
inhibitor like Ranolazine.
3.4.1 FGF12A modulates NaV channel inactivation through VSD-IV regulation
A co-expression of FGF12A increased NaV1.5 steady-state availability without affecting the voltagedependence of its activation. FGF12A did not alter the recovery from inactivation but modulated the fast
inactivation kinetics, by biasing the channels undergoing open-state inactivation towards fast inactivation
across all depolarizing potentials. In our recent work, we compared the mechanisms of regulations between
two iFGF isoforms, FGF12B and FGF13VY, that are dominant in human and mouse hearts accordingly and
found similar regulatory effects on NaV channel inactivation (Angsutararux et al., submitted). The
depolarizing shifts in SSI were also reported in other studies of different NaV and iFGF isoforms (Liu et al.,
2003) (Yang et al., 2016) (Wang et al., 2011a) (Wang et al., 2012) (Effraim et al., 2019). We identified the
same FGF12A regulation of VSD-IV activation, as in our previous work on FGF12B and FGF13VY
(Angsutararux et al., submitted). The regulation of VSD-IV and VSD-III kinetics was previously shown to
affect NaV1.5 inactivation (Hsu et al., 2017).
The effect of FGF12A on SSI also relied on an inactivation gate (IFMT motif), as shown in IFM/IQM
NaV1.5. When an inactivation gate is impaired, the FGF12A-mediated shift in SSI was no longer detected. In
general, iFGFs show similar regulation mechanism on NaV1.5, by modulating the activation of VSD-IV to
mediate inactivation kinetics and through the interaction with III-IV linker, to affect steady-state inactivation.
71

3.4.2 FGF12A is a late INa inhibitor
The expression of FGF12A in IQM NaV1.5 significantly reduced late INa. This phenomenon has not been
observed prior with FGF12B nor FGF13VY. We thus speculate the potential of FGF12A as a late INa inhibitor
in inactivation impaired NaV channels. Indeed, the N-terminus of FGF12A (amino acid 2-21) likely contains
an inactivation particle as suggested by other studies (Dover et al., 2010) (Venkatesan et al., 2014). The
distinct kinetics of recovery from inactivation and inactivation time constant of FGF12A expressed with IQM
NaV1.5 suggests the unique mechanism of FGF12A inactivation particle that is different from IFMT motif.
We showed that FGF12A can reduce the percentage of late INa in LQT3-linked NaV variants. The LQT3
syndrome is caused by mutations in NaV1.5 that disrupt NaV channel inactivation leading to sustained late INa
(Wang et al., 1996). The resulting prolonged QT duration predisposes patients to fatal arrhythmias. FGF12A
was an effective late INa inhibitor for most LQT3-linked variants on III-IV linker and the CTD we studied.
There were, however, differences in the level of late INa observed between Xenopus oocytes expression
system and HEK cells from past studies, for two variants E1901Q and Q1909R. The lack of late INa in
Xenopus oocytes might be due to the high CaM expression (Yan et al., 2017) or the elevated Ca2+
concentration (Abdelsayed et al., 2017) that rescue defective CaM binding.
The cryo-EM structure of cockroach NaVPaS channel included the CTD interaction with III-IV linker via
equivalent residue pair E1784-K1493 in NaV1.5 (Shen et al., 2017). The interaction sites were also tested in
another study using isothermal titration calorimetry (ITC) and NMR spectroscopy (Gardill et al., 2018). They
were mapped to III-IV linker K1504/K1505 and the EF-hand domain in the CTD. Here, we observed the
higher FGF12A blocking efficiency in LQT3-linked variants closer to these identified sites (ΔK1500, ΔKPQ,
Y1795C vs F1473S, S1904L), hinting at the significance of III-IV linker and the CTD interaction on FGF12A
inactivation particle function.
We also found accelerated inactivation kinetics upon FGF12A co-expression for most LQT3-linked variants,
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except Y1795C. A significantly slower inactivation kinetic, over early depolarization (20 ms), occurred in
Y1795C NaV1.5 when FGF12A was expressed. Yet, sustained late INa during prolonged depolarization (100
ms) was significantly reduced. This Y1795 is an interesting residue. Multiple mutations can register to
various phenotypically distinct conditions. Three variants, Y1795C, Y1795H and Y1795insD result in LQT3,
Brugada and mixed phenotype syndromes accordingly (Vecchietti et al., 2007) (Rivolta et al., 2001). A study
demonstrated that Y1795C disrupted the heterodimer interaction between the CTD of one NaV1.5 and CaM
bound to the CTD of the other NaV1.5 (Gabelli et al., 2014) (Yan et al., 2017). The mutation might affect
iFGF binding conformation and a coupling between NaV channel dimers.
Additionally, FGF12A caused the depolarizing shifts in SSI for all LQT3-linked variants. There were,
however, differences in the magnitude of V1/2 alteration. For LQT3-linked variants in III-IV linker, FGF12A
induced the similar change in SSI V1/2 as in WT NaV1.5. When variants occurred in the CTD, that affect CaM
binding affinities, FGF12A caused the larger depolarizing shifts in SSI V1/2, almost twice as much as in WT
NaV1.5. This difference suggests an important, but non-essential role of CaM in FGF12A regulation of
NaV1.5. Recent study demonstrated that iFGF N-terminal domain also contains CaM binding site, further
down an inactivation particle region (Mahling et al., 2021). It is possible that CaM, with reduced affinities in
LQT3-linked variants, preferentially binds to the FGF12A N-terminus and affect the NaV channel availability.
CaM binding on its N-terminus might alter FGF12A conformation on the NaV1.5 CTD, and its regulation of
SSI. A model was proposed based on a chimeric structure of NaV1.7-NaVPaS with α-scorpion toxin that at
resting state, the NaV CTD interacts with VSD-IV, resulting in sequestered III-IV linker. Upon VSD-IV
activation, III-IV linker is released to move the IFMT motif to its binding site (Clairfeuille et al., 2019). The
binding of CaM and iFGF on the CTD could cooperatively modulate such interactions (Gade et al., 2020)
(Abrams et al., 2020) (Kang et al., 2021).
3.4.3 FGF12A modifies the pharmacology of late INa inhibitor, Ranolazine
Ranolazine is the specific late INa inhibitor (Rayner-Hartley & Sedlak, 2016) that shows potential clinical
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benefits in patients with LQT3 (Scirica et al., 2007) (Moss et al., 2008) (Chorin et al., 2016). It is
recommended in the guideline by the American College of Cardiology Foundation and the American Heart
Association for patients with stable ischemic heart disease that are unable to use acceptable dose of βblockers. In clinical trials of patients with stable angina, Ranolazine treatment improved exercise performance
and reduced exercise-induced myocardial ischemia (Chaitman et al., 2004) (Thadani, 2004). Ranolazine,
however, failed to diminish major cardiovascular end point of death, myocardial infarction, or severe
recurrent ischemia in patients with non-ST-elevation acute coronary syndromes (ACS) (Morrow et al., 2007).
Possibly, the increased expression of FGF12A we found in HF patients might attenuate Ranolazine efficacy.
We showed here that the expression of FGF12A can alter the pharmacology of Ranolazine.
Since FGF12A is also the late INa inhibitor, with an even greater efficiency than Ranolazine, its expression
rendered Ranolazine less beneficial, even though it did not change Ranolazine’s ability to inhibit late INa.
FGF12A, however, altered the Ranolazine profile on peak current inhibition. Ranolazine conferred greater
blocking efficiency towards peak than late current, in the presence of FGF12A for IQM NaV1.5, but not WT
NaV1.5. The binding of FGF12A inactivation particle could possibly alter the Ranolazine binding affinity.
The binding of FGF12A inactivation particle might be in the similar region as Ranolazine binding site, around
the common local anesthetic (LA) drug binding site F1760 (Abrams et al., 2020) (Fredj et al., 2009). Since
FGF12A only participated in NaV channel inactivation when the IFMT motif was compromised, we did not
observe the FGF12A modulation of Ranolazine in WT NaV1.5. Another possibility is that FGF12A modulate
Ranolazine effect through VSD regulation, as previously shown for Mexilitine (Zhu et al., 2019), and
Lidocaine and Ranolazine modulation by β-subunits (Zhu et al., 2021).
3.4.4 Significance of FGF12A in pathophysiology of cardiac diseases
FGF12A demonstrated its high blocking efficiency towards late INa, suggesting its potential protective roles in
HF patients. Even though we reported here an increase in expression of FGF12A in HF patients that should be
beneficial, the amount of FGF12A might not be high enough to revert late INa, or the time of this alteration
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happens too late during the stage where it is no longer beneficial. The reduction of late INa during early stage
of HF could provide more benefits for the prevention of HF progression. It remains to be tested whether this
FGF12A inactivation particle works in NaV channel modified by CaMKII, the likely cause of increased late
INa in HF (Maltsev et al., 2007) (Horvath & Bers, 2014). iFGF was also reported to regulate cardiac calcium
channel CaV1.2 (Hennessey et al., 2013). The regulation of iFGF, especially the balance of iFGF isoforms,
thus represents the novel therapeutic target for cardiac arrhythmias.
3.4.5 Limitations
Our specific study of NaV1.5 and FGF12A co-expression omits the complicated environment of native
cardiomyocytes. A multimolecular complex of NaV channels is formed by myriad of regulatory subunits.
These auxiliary subunits such as β-subunits also modulate NaV1.5 through VSD regulation (Zhu et al., 2017)
(Angsutararux et al., 2021). A thorough investigation of multiple subunits combined should be addressed in
the future. The difference in an expression system, Xenous oocytes vs HEK cells, can also contribute to the
disparities reported between different studies, especially when the intracellular CaM and Ca2+ concentrations
are of significant roles. In this study, we haven’t observed the FGF12A effect on a long-term inactivation of
NaV1.5, as reported in previous studies (Dover et al., 2010). The discrepancy could be pertaining to the study
system, and careful consideration is needed to realize the full potential of FGF12A in antiarrhythmic
treatment.

3.5 Conclusion
We have shown the mechanism of FGF12A modulation of NaV1.5 inactivation kinetics and steady state
inactivation is through the regulation of VSD-IV kinetics. We presented the novel role of FGF12A as the late
INa inhibitor in pathophysiology of cardiac diseases. FGF12A can effectively reduce late INa in congenital
LQT3-linked NaV1.5 variants, while increasing the channel availability. These combined effects of FGF12A
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can be beneficial towards the treatment of cardiac arrhythmias. We proved the potential protective roles of
increased FGF12A expression in HF patients and put forward its therapeutic values for the early treatment of
HF.

3.6 Materials and Methods
3.6.1 Molecular biology
Plasmid constructs were made for human FGF12A (UniProtKB identifier: P61328-1) and human NaV1.5
(UniprotKB identifier: Q14524-1) on pBSTA and pMAX vectors, respectively. The constructs for voltageclamp fluorometry (VCF) studies were made in the background of C373Y and Y1977A mutations, to ensure
maximal fluorescence signal expression (Varga et al., 2015). Then, a cysteine mutation was engineered into
each voltage sensor domain (VSD): V215C for VSD-I, S805C for VSD-II, M1296C for VSD-III and S1618C
for VSD-IV in separate constructs. Our lab has previously shown these mutations yield the optimal sensitivity
without significantly altering NaV1.5 gating kinetics (Varga et al., 2015).
All LQT3-linked variants in this study were made using primers with overlap extension and high-fidelity
polymerase chain reaction (PCR). The plasmids were purified with Midiprep (MACHEREY-NAGEL) and
sequenced to confirm a successful mutagenesis. Then, the capped mRNA was made with mMESSAGE
mMACHINE T7 transcription kit (Thermo Fisher Scientific).
3.6.2 Xenopus oocyte cut-open recording and voltage-clamp fluorometry
Oocytes were obtained from Xenopus laevis by laparotomy according to the protocol #21-0371 (approved by
the Washington University Institutional Animal Care and Use Committee). Oocytes were harvested and
injected with mRNAs for the total of 40-80 ng per cell. FGF12A was co-injected with NaV1.5 at a 4:1 molar
ratio. Oocytes were incubated at 18°C for 3-5 days in ND93 solution (93 mM NaCl, 5 mM KCl, 1.8 mM
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CaCl2, 1 mM MgCl2, 5 mM HEPES, 2.5 mM Na-pyruvate, and 1% penicillin-streptomycin, pH7.4). Cut-open
oocyte recordings were performed with a CA-1B amplifier (Dagan Corporation) and Clampex software (v10;
Molecular Devices). The oocyte chamber was temperature controlled to 19°C with an HCC-100A temperature
controller (Dagan Corporation). The external recording solution consists of 25 mM NMG-Mes, 90 mM NaMes, 20 mM HEPES, and 2 mM Ca-Mes2, with pH adjusted to 7.4. The internal recording solution contains
105 mM NMG-Mes, 10 mM Na-Mes, 20 mM HEPES, and 2 mM EGTA, adjusted to pH 7.4. Ranolazine
dihydrochloride (SelleckChem) was dissolved in the external recording solution at a concentration of 4
mmol/L, and was perfused manually in the oocyte chamber.
For the VCF protocol (Rudokas et al., 2014), oocytes were labeled with 10 µM methanethiosulfonatecarboxytetramethylrhodamine (MTS-TAMRA; Santa Cruz Biotechnology) in a depolarizing solution (110
mM KCl, 1.5 mM MgCl2, 0.8 mM CaCl2, 0.2 mM EDTA, and 10 mM HEPES, pH 7.1) for 30 minutes on ice
in the dark. A teal LED light at 510/25 nM wavelength (SPECTRA X, Lumencor) was used to excite the
fluorophore and the emission light was measured with a photodiode PIN-040A (United Detector Technology)
and an Axopatch-200A amplifier (Molecular Devices). The fluorescence traces were collected simultaneously
with the ionic current over the activation protocol and averaged over 10 runs.
3.6.3 Electrophysiology data analysis
For each recording, the membrane capacitance was compensated and the P/-8 leak subtraction was performed.
The data were analyzed with Clampfit software (v10; Molecular Devices) and Excel (Microsoft). The voltagedependence of activation and steady-state inactivation curves were fitted to a Boltzmann equation
G(V) = (1+exp(V1/2-V)/k)-1
where G(V) is the conductance normalized between 0 and 1, V is the test voltage (mV), V1/2 is the halfmaximal voltage, and k is the slope factor.
The recovery from inactivation is fitted to a double exponential function
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G(V) = C - A1·exp(-t/ Ƭ 1) – A2·exp(-t/Ƭ2)
where t is the recovery duration (s), C is the constant, A1 and A2 are the fractional amplitudes, and Ƭ1 and Ƭ2
are the recovery time constants.
The normalized peak current decay was fitted to a bi-exponential function
I(t) = Aslow ·exp(-t/ Ƭ slow) + Afast·exp(-t/ Ƭ fast)
Where t is the decay time (s), Aslow and Afast are the fractional amplitudes, and тslow and тfast are inactivation
time constants.
The % late current was calculated as the average current during the last 10 ms of the 100-ms depolarizing
pulse, normalized to the peak current.
The fluorescence data was low pass filtered at 1 kHz before baseline subtracting to correct for
photobleaching. At -120 mV, which is the resting potentials before and after activation pulses, the
fluorescence trace was fitted to a 4-term exponential function and served as the baseline with no change in
fluorescence. The change in fluorescence signal relative to the baseline fluorescence (ΔF) was then calculated
for each membrane potential. The voltage-dependence of Fluorescence signal (F-V) curve was fitted to the
Boltzmann equation.
3.6.4 Statistical analysis
Statistical analysis was performed via Prism9 software (GraphPad). The data was collected from the sample
size of 3-10. The statistical significance between 2 groups was tested by an unpaired student t-test. The
significant difference was determined by the p-value of less than 0.05 (*), 0.01 (**) and 0.001 (***).
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3.8 Supplementary Figures

Figure S3.1: The N-terminus of FGF12A is responsible for the late INa inhibition
(A) The deletion of amino acids 2-22 of FGF12A abolished its ability to reduce late INa in IQM NaV1.5. (B) Exemplary
traces of INa at -20 mV.

Figure S3.2: FGF13A shows similar effects as FGF12A in IQM NaV1.5
(A) Alignment of FGF12A and FGF13A showed conserved sequence at the N-terminus. (B) FGF13A reduced % late INa in
IQM NaV1.5 at all membrane potentials. (C) Exemplary INa traces at -20 mV showed reduced late INa in IQM NaV1.5 by
FGF13A. (D) FGF13A induced more complete inactivation at steady state. (E) Recovery from inactivation curve showed
unique mechanism of FGF13A as an inactivation particle.
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Figure S3.3: FGF12A induced a larger change in SSI V1/2 in LQT3-linked variants on the CTD relative to WT
NaV1.5
For LQT3-linked NaV1.5 variants that are registered to III-IV linker, FGF12A caused a similar shift in SSI V1/2 as in WT
NaV1.5. However, when mutations occur in the CTD, that affect the CaM binding affinity, FGF12A induced a larger
change in SSI V1/2.

Figure S3.4: FGF12A does not affect Ranolazine pharmacology in WT Na V1.5
(A) Ranolazine reduced peak INa of WT NaV1.5 and NaV1.5 with FGF12A. (B) FGF12A did not alter Ranolazine tonic
block (left) nor use-dependent block (right) in WT NaV1.5.
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Chapter 4: FlAsH-based FRET assay to investigate
dynamics of NaV channel inactivation

4.1 Abstract
The voltage-gated sodium channels (NaV) are responsible for initiating and propagating an action potential
(AP), the electrical signal generated by excitable cells such as cardiomyocytes and neurons. The inactivation
of NaV channel is a complicated process, involving many parts of the channel and various auxiliary subunits:
(1) the NaV inactivation gate, (2) the NaV C-terminal domain (CTD), (3) Calmodulin (CaM), and (4)
intracellular fibroblast growth factor (iFGF). How these components regulate the NaV channel inactivation is
not well understood. In this study, we developed a Fluoresceine Arsenical Hairpin (FlAsH)-based FRET assay
that allows the fluorescent tagging within NaV channel inactivation gate without disrupting its function. We
engineered the short Tetracystein (TC) tag into NaV channels for the specific FlAsH labeling. We showed that
this assay could be applied to test the models and hypotheses of NaV channel inactivation. This newly
developed tool will help us gain insights into the dynamics of NaV channel inactivation.

4.2 Introduction
An action potential (AP) is the electrical signal generated in excitable cells like myocytes and neurons.
Underlying the upstroke or the rising phase of AP is the inward Na+ current (INa). Voltage-gated sodium
channels (NaV) are thus responsible for the initiation and propagation of AP. Usually, NaV channels activate
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to depolarize membrane potential, and inactivate within a few milliseconds, to facilitate AP termination. An
irregular inactivation of NaV channel could lead to sustained late INa, which is pro-arrhythmic.
NaV α-subunit consists of 4 homologous repeats (I-IV), connected through intracellular linkers. Each repeat
contains 6 membrane segments (S1-S6), constituting the voltage-sensor domain (VSD, S1-S4) and the pore
module (S5-S6). Between repeats III and IV (III-IV linker) is a short linker where the inactivation gate, also
known as the IFMT motif, resides (Hartmann et al., 1994). NaV channel inactivation also involves another
part of the channel, the C-terminal domain (CTD) (Goldin et al., 2003) and auxiliary subunits that bind to the
CTD, including Calmodulin (CaM) and intracellular fibroblast growth factor (iFGF) (Wang et al., 2012)
(Wang et al., 2014).
Studies of NaV CTD truncation and the role of CTD in different NaV subtypes supported the significance of
the CTD on NaV channel inactivation (Descheênes et al., 2001) (Mantegazza et al., 2001). Yet, its regulatory
mechanisms are not well understood. Recently, a structure of the cockroach NaVPaS channel suggested the
direct interaction between the III-IV linker and the CTD (Shen et al., 2017) (Clairfeuille et al., 2019). The
charge reversal mutations of the interacting interfaces (K1493E and E1784K) yield increased late INa (Gade et
al., 2020) (Gardill et al., 2018). CaM and iFGF were hypothesized to promote this interaction during a closed
state through their binding to the CTD (Gade et al., 2020). iFGF interacts with the proximal part of the CTD
that forms the globular domain (Chagot et al., 2009), also known as the EF-hand domain, whereas the distal
portion of the CTD contains the CaM binding site, or the IQ motif (Bahler & Rhoads, 2002).
CaM is a Ca2+-sensing protein. CaM is postulated to be the key regulator of Ca2+-dependent change in NaV
channel inactivation. With elevated Ca2+ concentration, CaM caused the depolarizing shifts in steady-state
inactivation (Gabelli et al., 2016). CaM consists of two globular domains, N- and C-lobes. Each lobe can bind
to 2 Ca2+ ions and change its conformation. Based on several available structures of CaM bound to the NaV
CTD under various conditions, the model was proposed that upon Ca2+ elevation following NaV inactivation,
CaM is released from the CTD IQ motif to interact with the III-IV linker (Sarhan et al., 2012) (Johnson et al.,
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2018). CaM interaction with the III-IV linker destabilizes the inactivation gate and facilitates recovery from
inactivation (Johnson et al., 2018). The presence of iFGFs might modulate CaM regulation of NaV channel
gating (Liu, 2003) (Musa, 2015) (Hennessey, 2013) (Wang, 2011).
These mechanistic models were primarily based on the binding affinities, or the NMR structure determined
between CaM and purified short peptides of specific NaV channel segments. So far, the interaction between
the III-IV linker and the CTD has not been tested in a whole NaV channel complex in a cellular environment.
In this study, we developed the tool to investigate the interaction between the III-IV linker and the CTD of an
intact NaV channel. Using a Fluorescence Resonance Energy Transfer (FRET) technique combined with the
Fluoresceine Arsenical Hairpin (FlAsH) dye, we examined the contributions from auxiliary subunits, CaM
and iFGF, to the NaV channel inactivation. We explored (1) how CaM interact with III-IV linker, (2) whether
iFGF interacts with the III-IV linker, and (3) the interaction dynamic between the III-IV linker and the CTD
during inactivation.

4.3 Results
4.3.1 Incorporation of the Tetracysteine (TC) tag into NaV1.5 III-IV linker produces functional channel
The main challenge for our study is to introduce fluorescence dye in the III-IV linker without disrupting the
NaV channel function. Conventional fluorescent proteins such as Green Fluorescent Protein (GFP) are too
large for our purpose. Instead, we used small fluorescence dye, Fluorescein Arsenical Hairpin binderEthanedithiol (FlAsH-EDT2), that can bind specifically to the short Tetracysteine (TC) tag, consisting of 6
amino acids CCAGCC.
We engineered the TC tag into multiple regions on the III-IV linker of NaV1.5 that is not mutational hotspots
(Fig 4.1A) through specific point mutations. We measured the ionic sodium currents (INa) of these III-IV
linker TC NaV1.5s in HEK-293 cells and found them all expressed (Fig 4.1B). However, we noticed
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alterations in the NaV channel inactivation for some NaV1.5s with TC tags. Out of the 6 different positions of
TC tag we tested (1468TC, 1474TC, 1490TC, 1494TC, 1509TC, and 1515TC), 2 locations showed the most
disturbing effects on the NaV channel inactivation – 1468TC and 1490TC. The incorporation of the TC tag
allowed for specific labeling with FlAsH-EDT2, as demonstrated by HEK cells expressed TC fused to the end
of Cerulean (Fig 4.1C).
4.3.2 FlAsH-based FRET assay can be used to probe CaM interaction sites on NaV1.5
Fluorescence Resonance Energy Transfer (FRET) is a distance-dependent nonradiative transfer of energy
from the excited fluorophore (Donor) to another fluorophore (Acceptor). FRET efficiency is a good
measurement of molecular proximity within short distances (10 – 100 A°) (Babu Sekar & Periasamy, 2003).
A previous study showed that Cerulean, an enhanced Cyan Fluorescent Protein (CFP) is a suitable donor for
FlAsH-EDT2 (Hoffmann et al., 2005), which has similar fluorescence as Yellow Fluorescent Protein (YFP).
We made the control constructs that link the TC tag to Cerulean at varying linker lengths: 32, 64, and 128
amino acids (Glycine) in between (Fig. S4.1A). We measured FRET efficiency using our custom “threecube” FRET microscope (see methods) and found an inverse correlation between the linker distances and the
FRET efficiencies (Fig. S4.1B).
We tested the FlAsH-based FRET assay by probing the interactions between CaM and its binding site or the
IQ motif. We constructed NaV1.5 with the TC tag around the IQ (1908-1909) motif (1896TC, 1911TC,
1917TC, 1922TC, and 1928insTC) (Fig 4.2A) and fused Cerulean to the C-terminus of CaM (CaM_Cer). We
measured their FRET efficiencies and observed low efficiencies close to the binding sites (1896TC, 1911TC,
and 1917TC) (Fig 4.2B). Higher FRET efficiencies were detected when the TC tags were further away
(1922TC and 1928insTC), at more than 10 amino acids apart (Fig 4.2B). The low FRET efficiencies at the
binding sites could imply that the CaM_Cer binding prevents FlAsH dye from accessing the TC tag, and
hence no FRET occurs. This result suggests the pattern of measured FRET efficiencies could estimate the
binding site.
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Figure 4.1: Electrophysiology of NaV1.5 with tetracystein (TC) tags engineered to III-IV linker
(A) The structure of cardiac rat NaV1.5 (pdb: 6UZ3), highlighting the III-IV linker (blue) and the inactivation gate IFMT
motif (red), showed the sites of engineered TC tags. (B) Sodium current (INa) recordings of all III-IV linker TC NaV1.5s
expressed in HEK-293 cells showed functional channels. Some positions of TC tags (1468TC and 1490TC) caused
defective inactivation gating in NaV channels, while other positions (1474TC, 1494TC, 1509TC, and 1515TC) were less
disruptive. (C) Cells expressed Cerulean fused with TC tag showed specific labeling with FlAsH-EDT2.
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Figure 4.2: FlAsH-based FRET analysis of CaM interactions
(A) The structure of NaV1.5 C-terminal domain (CTD) (blue) in complex with CaM (yellow) (pdb: 4DCK) showed the
sites of TC tags around the IQ motif. (B) FRET efficiencies can be measured between CaM with Cerulean at the Cterminus (CaM_Cer) and IQ motif TC NaV1.5s labeled with FlAsH-EDT2. The distinct pattern showed no FRET
efficiency around the binding sites, but high FRET efficiencies when the TC tags were further away. (C) The IQ/AA
mutation was introduced into III-IV linker TC NaV1.5s, to use as the negative control when there is no CaM binding.
FRET efficiencies between CaM C-lobe (CaM_Cer) and III-IV linker were compared between WT and IQ/AA
background and showed no significant difference. (D) Cerulean was added to the N-terminus of CaM (Cer_CaM) to test
CaM N-lobe interaction with III-IV linker. In comparison to IQ/AA background, higher FRET efficiencies in WT
background implied that CaM N-lobe is close to III-IV linker but does not bind to it.

4.3.3 CaM does not bind to the III-IV linker but interacts with it through its N-lobe
Next, we examined whether CaM interacts with the III-IV linker and through which lobe. Cerulean was added
to CaM, either its N- or C-terminus (Cer_CaM and CaM_Cer). The IQ/AA mutation that removes CaM
binding was a negative control. We compared FRET efficiencies between CaM and III-IV linker TC NaV1.5s
in WT background to IQ/AA mutation. There was no FRET efficiency in 1928insTC IQ/AA NaV1.5 with
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neither Cer_CaM nor CaM_Cer, confirming the absence of CaM. Using CaM_Cer, we detected small FRET
efficiencies with III-IV linker TC NaV1.5s of WT background, which were not significantly higher than
IQ/AA background (Fig 4.2C). We concluded that the C-lobe of CaM was not close to the III-IV linker and
likely remained bound to the IQ motif.
In contrast, Cerulean attached to the N-lobe of CaM (Cer_CaM) yielded higher FRET efficiencies with almost
all III-IV linker TC NaV1.5 in WT background compared to IQ/AA background (Fig 4.2D). All positions of
TC tags on the III-IV linker produced similar FRET efficiencies. This result implies the potential interaction
between CaM N-lobe and III-IV linker, but not direct binding.
4.3.4 FGF12B also interacts with III-IV linker
We further investigated the interaction between FGF12B and NaV1.5. First, we confirmed the FRET
efficiencies between NaV CTD and FGF12B, by engineering TC tags to the EF-hand domain (1851TC,
1860TC, 1860insTC, 1866TC, 1880TC, and 1887TC) and fusing Cerulean to the N-terminus of FGF12B
(Cer_FGF12B) (Fig 4.3A). We selected the positions of TC tags around the FGF12 binding site. As expected,
we detected FRET efficiencies between EF-hand TC NaV1.5s and Cer_FGF12B. Interestingly, we did not
observe the same pattern of FRET efficiencies as CaM_Cer and IQ-motif TC NaV1.5s. All EF-hand TC
NaV1.5s produced similar FRET efficiencies (Fig 4.3B). The difference in the FRET efficiencies pattern
implied a difference in interaction nature between FGF12B and CaM on the NaV1.5 CTD. Possibly, FGF12B
does not constitutively bind to the EF-hand domain but interact dynamically so that FlAsH-EDT2 dye can
access all TC tags. Another possibility is that FGF12B binds to the EF-hand domain with less affinity than
CaM on the IQ motif and thus does not prevent the FlAsH-EDT2 dye labeling.
Then, we tested FRET efficiencies between Cer_FGF12B and III-IV linker TC NaV1.5s. All positions of TC
tags yielded FRET efficiencies that were higher around the IFMT motif (1485-1488) (Fig 4.3C). FRET
efficiencies between III-IV linker TC NaV1.5s and Cer_FGF12B were larger than those measured with
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Cer_CaM, suggesting FGF12B is closer to III-IV linker than CaM N-lobe.

Figure 4.3: FlAsH-based FRET analysis of FGF12B interactions
(A) The structure of NaV1.5 CTD (blue) in complex with FGF13 (blue) (pdb: 4DCK) showed the sites of TC tags
around the EF-hand domain. (B) FRET efficiencies can be measured between FGF12B with Cerulean at the C-terminus
(FGF12B_Cer) and EF-hand TC NaV1.5s labeled with FlAsH-EDT2. All positions of TC tags showed similar FRET
efficiencies, implying that FGF12B does not bind tightly to EF-hand domain. (C) The IQ/AA mutation was introduced
into III-IV linker TC NaV1.5s, to use as the negative control when there is no CaM binding. FRET efficiencies between
CaM C-lobe (CaM_Cer) and III-IV linker were compared between WT and IQ/AA background and showed no
significant difference. (D) FRET efficiencies were measured between FGF12B_Cer and III-IV linker TC NaV1.5s
labeled with FlAsH-EDT2. All positions of TC tags showed similar FRET efficiencies.

4.3.5 FGF12B interaction remains in inactivation impaired NaV channels
Because FGF12B regulates the inactivation of NaV channel, we tested whether the impaired inactivation
affects FGF12B’s interaction with the III-IV linker. We mutated the IFMT motif to IQM mutation in the
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background of III-IV TC NaV1.5s and measured their FRET efficiencies with Cer_FGF12B. The comparison
of FRET efficiencies between WT and IQM backgrounds showed a slight decrease upon IQM mutation, but
the mutation did not abolish the interaction (Fig 4.4A).
We introduced another mutation E1784K to sever the interaction between the III-IV linker and the CTD. This
mutation also impairs fast inactivation, resulting in increased late INa. Still, we did not observe a significant
reduction in FRET efficiencies between FGF12B and NaV III-IV linker by E1784K relative to WT (Fig 4.4B).
These results informed us that FGF12B is close to III-IV linker, even when the inactivation was
compromised.

Figure 4.4: FGF12B interaction with III-IV linker remains in inactivation-impaired NaV channels
(A) The mutation of IFMT motif to IQM impairs fast inactivation. However, the interactions between FGF12B and IIIIV linker was not abolished. Slightly decrease in FRET efficiencies was observed. (B) The E1784K mutation severs
interaction between III-IV linker and the CTD and impairs inactivation. There was no significant difference in FRET
efficiencies between FGF12B and III-IV linker of E1784K background, relative to WT.

4.3.6 Conformational changes within the NaV channel during inactivation
All the FRET results we measured represented the interactions during a closed state. To investigate the
interactions during NaV channel inactivation, we used HEK-293 cells that stably express inward rectifying
potassium (Kir) channels (Shandell et al., 2019). Kir channels are common in excitable cells like myocytes.
They conduct inward K+ current (IK1) more than outward current. In low K+ solution (HBSS), Kir channels
conduct outward IK1, resulting in hyperpolarized membrane potential. When the solution was exchanged to
high K+, a huge inward IK1 depolarizes the membrane potential, leading to NaV channels activation. The
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perfusion of high K+ solution will induce NaV channels into the fast inactivated states.
We first determined the change in NaV CTD by attaching Venus to the very end of NaV1.5 CTD
(NaV1.5_Ven). For negative control, we co-expressed NaV1.5_Ven with Cerulean (Cer). As expected, most
cells yielded low FRET efficiency. The solution was exchanged from HBSS (pre) to HBSS with high K+ (100
mM KCl or 140 mM KCl) and back to HBSS (post). We calculated FRET efficiency and the change in FRET
efficiency relative to pre-solution exchange value per cell. Cells expressing negative control constructs
showed inconsistent FRET efficiency changes upon solution exchange, and the changes post-high K+ solution
did not return to 0 (Fig 4.5A). We then tested the interaction between NaV1.5 CTD and FGF12B with
Cerulean attached to the N-terminus (Cer_FGF12B) or CaM with Cerulean attached to the C-terminus
(CaM_Cer). With Cer_FGF12B, we noticed most of the changes occurred in the same direction (Fig 4.5B).
FRET efficiency increased upon high K+ solution and returned to almost the same level as pre-solution
exchange. The changes in FRET efficiency post-solution exchange were close to 0 for most cells (Fig 4.5B).
In contrast, with CaM_Cer, the changes in FRET efficiencies occurred in both directions (Fig 4.5C). Also,
post-solution exchange FRET efficiencies did not return to the pre-solution exchange values.
The following experiment examined the change in interactions between the III-IV linker and the CTD, or
auxiliary subunits, during inactivation. We picked NaV1.5 with a 1515TC tag because of its functional
inactivation gating. First, we tested the interaction with the very end of the CTD by adding Cerulean to the
NaV1.5 1515TC (NaV1.5 1515TC_Cer). We noticed a homogenous increase in FRET efficiency upon high K+
solution exchange and the return of FRET efficiencies close to the pre-solution exchange values (Fig 4.6A).
This result showed that the III-IV linker was more proximal to the CTD upon NaV channel inactivation. Then,
we studied the interactions between the III-IV linker (NaV1.5 1515TC) and Cer_FGF12B or CaM_Cer. We
observed the non-uniform changes in FRET efficiencies and the deviations in FRET efficiencies post-solution
exchange from pre-solution exchange values (Fig 4.6B, C).
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Figure 4.5: Changes in NaV CTD interactions during inactivation
We employed HEK cells that stably expressed inward rectifier K+ channel (K ir) for the study of NaV channel
inactivation. The exchange of low K+ solution to high K+ solution leads to large influx of K+ current through K ir (IK1)
and the depolarization of membrane potential. We measured FRET efficiency in low K + solution (pre), then perfused
with high K+ solution (100K and 140K) before switching back to low K+ solution (post). The change in FRET
efficiency was calculated, in relative to pre-solution exchange condition. (A) FRET efficiency between Cerulean and
Venus attached to the end of NaV1.5 CTD (NaV1.5_Ven) served as the negative control. We detected low FRET
efficiency and no uniform change during perfusion. (B) FRET efficiency between FGF12B with Cerulean attached to its
N-terminus and NaV1.5_Ven showed consistent increase in FRET efficiency during inactivation in most cells. The
change in FRET efficiency returned to almost 0 in post-solution exchange condition. (C) FRET efficiency between CaM
with Cerulean attached to its C-terminus and NaV1.5_Ven showed no uniformed change in FRET efficiency, similar to
negative control in (A).
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Figure 4.6: Changes in NaV III-IV linker interactions during inactivation
We used NaV1.5 with 1515TC to test III-IV linker interaction during inactivation. (A) Cerulean was added to the Cterminus of NaV1.5 1515TC and FRET efficiency was measured. Homogenous increase in FRET efficiency during
inactivation was detected. (B) FRET efficiency was measured between NaV1.5 1515TC and FGF12B with Cerulean
added to its N-terminus and showed no uniform change upon inactivation. (C) There was no consistent change in FRET
efficiency between NaV1.5 1515TC and CaM with Cerulean added to its C-terminus during inactivation.
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4.4 Discussion
NaV channel inactivation is a complicated process that involves multiple parts of the channel (III-IV linker
and the CTD) and many auxiliary subunits (CaM and iFGF). There is much debate about the mechanisms
involving all these components. Recent structures of eukaryotic NaV channels give insights into molecular
details of how the IFMT motif inactivates the NaV channel. However, the key CTD was missing. Here, we
developed the new tool of FlAsH-based FRET assay that incorporated the fluorescent dye into the III-IV
linker without disrupting NaV channel inactivation gating. This tool allows us to investigate the dynamics of
NaV channel inactivation. We can examine the interplay of NaV channel inactivation gate and the CTD,
including auxiliary subunits bound to it.
4.4.1 CaM C-lobe binds to the IQ motif and remains there during inactivation
Through FRET efficiency analysis combined with mutagenesis studies, we showed that CaM binds to the IQ
motif, specifically through its C-lobe. CaM N-lobe can interact with the III-IV linker but does not bind to it. It
is important to note that these interactions likely reflect closed-state channels in low Ca2+ conditions.
Depolarizing the membrane potential caused no significant change in FRET efficiencies between CaM C-lobe
and the NaV CTD or III-IV linker. These results implied that CaM C-lobe remains on the IQ motif during
inactivation. CaM does not entirely leave the IQ motif to bind to III-IV linker. How CaM N-lobe interacts
with III-IV linker change during inactivation or under elevated Ca2+ remains to be tested.
4.4.2 FGF12B interacts with the III-IV linker independent of the state of inactivation
Results showed that the C-terminus of FGF12B interacts with the III-IV linker similarly as it interacts with
the CTD EF-hand domain. Unlike CaM binding to the IQ motif, FGF12B does not bind tightly to the CTD, as
observed by the different patterns of FRET efficiencies. Interacting sites between the III-IV linker and the
CTD were identified at K1493-E1784 in NaV1.5. Surprisingly, the charge reversal E1784K mutation did not
affect the FRET efficiencies between FGF12B and III-IV linker, suggesting more extensive interactions
99

between 2 parts. The recent cryo-EM structure of E1784K NaV1.5 also illustrates the exact orientation of the
III-IV linker in E1784K, as in WT NaV1.5 (Li et al., 2021).
Further examination of the inactivation impaired channel IFM/IQM NaV1.5 showed a slight reduction in
FRET efficiencies between FGF12B and III-IV linker, but not total absence. The structure of the NaV channel
with QQQ mutation in the IFMT motif showed a flexible III-IV linker (Jiang et al., 2021), the IQM mutation
might not be as severe as the QQQ mutation, and some helical structure may retain in the III-IV linker
allowing for its interaction with the CTD. Altogether, these results implied no substantial change in the
interactions between NaV CTD EF-hand domain and III-IV linker even when inactivation is impaired.
Potentially, FGF12B promotes or stabilizes the interaction between the III-IV linker and the CTD (Gade et
al., 2020).
We observed no significant change when we measured the change in FRET efficiency between NaV1.5
1515TC and Cer_FGF12B during inactivation. Instead, there was an increase in FRET efficiency between the
FGF12B N-terminus and the end of NaV CTD. This change in FRET efficiency supports the intermolecular
interaction model between the CTD of two NaV1.5s, showing contacts between the EF-hand domain of one
NaV1.5 and the end of CTD of another NaV1.5 (Gabelli et al., 2014). This model also agrees with the increase
in FRET efficiency between the III-IV linker and the end of NaV CTD that we observed. Our results
suggested that during inactivation, the end of one NaV CTD can interact with the EF-hand domain of another
NaV CTD. This EF-hand domain remains near the III-IV linker and interacts with FGF12B.
4.4.3 Limitations and future directions
In this study, the FRET efficiencies that we measured were relatively low (< 0.2), and low FRET efficiency
can limit the assay’s sensitivity. We also noticed the wide range of FRET efficiencies, likely due to variable
transfection efficiencies among different cells. FRET efficiency depends on the concentration of both Donor
and Acceptor fluorophores and their relative ratios. If there is a much higher Donor concentration than
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Acceptor, then measured FRET efficiency will be small. On the contrary, the much higher Acceptor
concentration relative to Donor will make the FRET correction during analysis inaccurate. We measured
FRET efficiency for an individual cell. We cannot control how much each cell will express Donor and
Acceptor molecules. Obtaining data from a larger number of cells could help reduce variabilities in FRET
efficiencies.
We used a perfusion system to depolarize the membrane potential and induce NaV channels into inactivation.
The slow exchange of the old and the new solution limits our ability to measure the spontaneous change in
FRET efficiency. We have to wait for a few minutes to ensure a complete solution exchange before taking the
FRET image. This procedure means that we can only observe the change in FRET efficiency over steady-state
inactivation. The fast inactivation dynamics within a range of a few milliseconds are impossible to measure
with our current perfusion setup. To do so, we will need to apply a patch-clamp fluorometry technique to our
FlAsH-based FRET assay. The simultaneous measurements of fluorescence signals and ionic current will
allow us to track the rapid conformation changes within the NaV channel during the fast inactivation.

4.5 Materials and Methods
4.5.1 Molecular biology
All Tetracysteine (TC) tags were introduced into SCN5A gene, encoded for NaV1.5 (UniprotKB identifier:
Q14524-1), by replacing the 6 amino acids starting from the indicated number with CCPGCC. Primers, with
overlap extension, were made commercially (Integrated DNA Technologies, Coralville, IA). We used a twostep PCR approach to engineer the TC tag into NaV1.5 plasmid. We added Cerulean or Venus sequences to
either N- or C-terminus of CaM and FGF12B with a GSGSGS linker in between.
The engineered plasmids were transformed into E.coli competent cells. The colony was picked and expanded.
We purified the engineered DNA plasmids using Miniprep (MACHEREY-NAGEL), and the plasmids were
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sequenced to confirm successful mutagenesis.
4.5.2 Cell culture and plasmid transfection
HEK-293 cells and HEK-293 stably expressed Kir were maintained in HEK medium containing DMEM basal
medium (Gibco) with 10% Fetal Bovine Serum (Gibco) and 100 U/ml Penicillin-Streptomycin (Lonza
Bioscience), at 37 °C and 5% CO2. Cells were passaged every 2-3 days when they reached 80% confluency,
using TrypLE Express (Gibco). For transfection, HEK-293 cells were seeded one day before the transfection
in a 35-mm dish one day to get approximately 60% confluency. A total of 60 ng DNA was transfected per
each 35-mm dish, using jetOPTIMUS reagent (Polyplus) following the company’s protocol. We used a 2:1
mass ratio between NaV1.5 and CaM or NaV1.5 and FGF12B (equivalent to a 4:1 molar ratio).
4.5.3 FlAsH-EDT2 labeling
We followed the protocol adapted from Hoffmann et al. (Hoffmann et al., 2010). In brief, cells were washed
three times with Hank’s balanced salt solution (HBSS) containing CaCl2 and MgCl2 (Gibco) and incubated at
37 °C for 1 hr with 500 nM FlAsH-EDT2 (Cayman Chemical) and 12.5 µM EDT2 in HBSS. Next, cells were
rinsed and incubated in HBSS containing 50 mM 2,3-dimercaptoproponol (British anti-Lewisite or BAL)
wash for 20 min at 37 °C to block nonspecific labeling. Lastly, cells were washed three times with HBSS to
remove residual BAL solution. Cells were kept at 37 °C until imagining, usually within a few hours.
4.5.4 FRET imaging
FRET imaging was done within 24-48 hrs after the transfection of the cells. The old medium was aspirated,
and cells were washed three times with HBSS. We imaged the cells in either HBSS (low K+ solution) or
HBSS with 100 mM and 140 mM KCl (high K+ solution). We used a Nikon Eclipse Ti-U inverted microscope
customed to the “3-cube” FRET setting. The LED light source Spectra III (Lumencor) provides excitation for
Cerulean (excitation filter: 440/20) and Venus or FlAsH (excitation filter: 510/25 nm) via CFP and YFP lines
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accordingly. Cerulean is enhanced Cyan Fluorescent Protein (CFP), and Venus is enhanced Yellow
Fluorescent Protein (YFP). FlAsH-EDT2 shares similar fluorescence as YFP.
The microscope was outfitted with a triple-band dichroic beamsplitter (FF459/526/596-Di01, Semrock) and a
triple-band emitter (FF01-475/543/702-25, Semrock) to reduce background illumination from the irrelevant
wavelength. The fluorescence output was passed into an OptoSplit II Bypass emission image splitter (Cairn
Research) fitted with a 505nm beamsplitter (T5051pxr, Chroma Color Corporation). The emission signal was
separated into two channels with the filters for Cerulean (emission filter: ET480/40 nm, Chromo Color
Corporation) and Venus (emission filter: ET545/50nm, Chroma Color Corporation) wavelengths. The image
was acquired via an Andor iXon EMCCD camera (Andor Technology), utilizing one-half of the camera
sensor for each emission channel and capturing two signals simultaneously. The Spectra III light engine and
Andor iXon EMCCD camera were controlled via a Digidata 1440A (Molecular Devices), driven by pClamp
software (Molecular Devices).
The system activated Cerulean excitation for 1 second, and the camera captured the image at a 10-ms delay.
Then, the Venus or FlAsH excitation was triggered to repeat the imaging process. Each image displayed the
Cerulean emission channel in one half of the screen and the Venus emission channel in the other half. A total
of 3 FRET channels were collected per sample: (1) the donor channel (excitation: 440/20, emission: 480/40),
(2) the FRET channel (excitation: 440/20, emission: 545/50), and (3) the acceptor channel (excitation: 510/25,
emission: 545/50).
4.5.5 FRET Data analysis
FRET data were analyzed with MATLAB (MathWorks) using a code developed in the lab. For each acquired
data, three images from (1) donor channel, (2) FRET channel, and (3) acceptor channel were calculated for
fluorescence signals as background-subtracted and cell average. We obtained S(Donor), S(FRET), and
S(Acceptor) for each data. We used two controls, cells expressed with Donor fluorophore only and cells
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expressed with Acceptor fluorophore only, to correct for signal crosstalk or the direct emissions from Donor
and Acceptor fluorophores when excited with Cerulean excitation. Two constants, RD1 and RA1, were
calculated.
𝑆(𝐹𝑅𝐸𝑇)

𝑅𝐷1 = 𝑆(𝐷𝑜𝑛𝑜𝑟) from cells expressing only Donor fluorophore

𝑅𝐴1 =

𝑆(𝐹𝑅𝐸𝑇)
𝑆(𝐴𝑐𝑐𝑒𝑝𝑡𝑜𝑟)

from cells expressing only Acceptor fluorophore

The corrected FRET signal (AFRET) was then calculated from cells expressing both Donor and Acceptor
fluorophores by subtracting the direct emission of Donor (DDirect) and Acceptor (ADirect).
AFRET = S(FRET) – DDirect – ADirect
where DDirect = RD1·S(Donor) and ADirect = RA1·S(Acceptor)
The apparent FRET efficiency can be reported using either an acceptor-centric (EA) or a donor-centric (ED)
method
𝐸𝐴 =

𝐴𝐹𝑅𝐸𝑇 𝑔(𝐴)
∙
𝐴𝐷𝑖𝑟𝑒𝑐𝑡 𝑔(𝐷)

and

𝐸𝐷 =

𝐴𝐹𝑅𝐸𝑇
𝐴𝐹𝑅𝐸𝑇+

𝑓(𝐴)
∙𝐷𝐷𝑖𝑟𝑒𝑐𝑡
𝑓(𝐷)

where g(A)/g(D) and f(A)/f(D) are constants related to the properties of fluorophores used and microscope
specification. They can be calculated from the control constructs that link Donor and Acceptor fluorophores
directly with linkers of varying lengths (Ben-Johny et al., 2016) (Butz et al., 2016). These constants were
obtained multiple times to ensure the stable FRET setup.
The number of Donor and Acceptor molecules could be estimated as the following
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[𝐷𝑜𝑛𝑜𝑟] =

[𝑅𝑒𝑐𝑒𝑝𝑡𝑜𝑟] =
𝑀𝐴

where 𝑀𝐷 =

𝑅𝐷1 ∙ 𝑆(𝐷𝑜𝑛𝑜𝑟)
(1 − 𝐸𝐷) ∙ 𝑀𝐷
𝑅𝐴1 ∙ 𝑆(𝐴𝑐𝑐𝑎𝑝𝑡𝑜𝑟)
𝑀𝐴

𝑓(𝐴)
⁄𝑓(𝐷)
𝑔(𝐴)
⁄𝑔(𝐷)

and MD can be set to 1
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4.7 Supplementary Figure

Figure S4.1: Control constructs of Cerulean fused with TC tag at varying linker
(A) Exemplary FRET images of 3 control constructs, Cerulean fused with TC of varying Glycine linker length-32, 64
and 128 residues. Images were shown from Donor, FRET, and Acceptor channels accordingly. (B) FRET efficiencies
reduced with Glycine linker lengths. The longer length means the larger distances between Donor and Acceptor
fluorophores.
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Chapter 5: Conclusions and Future Directions

NaV channels play a significant role in the regulation of cardiomyocyte excitability. Abnormalities in the
channel function could lead to cardiac diseases. NaV channel activation upon membrane depolarization is
followed shortly by its fast inactivation. This inactivation is crucial in limiting the late INa that sustains over a
long period. An incomplete inactivation results in elevated late INa, which leads to a prolonged AP duration
and a predisposition to arrhythmia. NaV channel inactivation is a complicated process involving multiple parts
of the channels and many auxiliary subunits. To fully understand the fast inactivation mechanism, insights
into the mechanism of individual components are needed. So far, the NaV channel auxiliary subunit iFGF
mechanism of regulation remains elusive. The interplays between different parts of the channels during
inactivation are also unexplored.

In this thesis, I successfully determined the molecular mechanism of iFGF regulation of cardiac NaV1.5
inactivation. I discovered that iFGFs modulate VSD-IV activation and the interactions between the NaV CTD
and III-IV linker. I demonstrated the significance of VSD-IV as a signaling hub for the regulation of NaV
channel inactivation gating. Other factors like the NaV β-subunit can also modulate this hub. I uncovered the
specific regulation of VSD-IV activation by different iFGF, which directly affects the composition of fast
inactivation. The earlier completion of VSD-IV activation leads to the inhibition of the slower component of
fast inactivation. Then, I demonstrated the implications of an alteration in iFGF isoform, an increase in
FGF12A expression observed in heart failure (HF) patients. This discovery provides a new paradigm of HF
pathophysiology since FGF12A exhibits a natural ability to prevent late INa. Its expression can also modulate
the pharmacological response of a specific late INa inhibitor and should be accounted for in targeted drug
therapy. Lastly, I developed a new tool to investigate the interplay between different components involved in
NaV channel inactivation. I can determine the interactions between the NaV channel inactivation gate on the
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III-IV linker and CaM and FGF12B bound to the NaV CTD. We presented the novel FlAsH-based FRET
assay, utilizing the Tetracysteine (TC) tag for fluorescent labeling on the NaV1.5 III-IV linker without
disrupting its function. This new tool enabled us to explore the proposed model of NaV channel inactivation
under various conditions.

I hope that our discovery will fill in the knowledge gap of the intricate inactivation process. The mechanistic
details of iFGF regulation of NaV1.5 inactivation could serve as a molecular basis for the more elaborate
model of NaV channel macromolecular complex. I hope that our newly developed tool for studying NaV
channel inactivation dynamics will help propel the discovery of new knowledge that will guide us toward
more efficient targeted treatment.
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